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Micro-ribonucleic acids (miRNAs) are non-coding RNAs that, in the majority of cases, regulate 
gene expression by binding to the 3’ untranslated region (UTR) sequence of target mRNAs to 
cause decreased mRNA levels. Recently, several studies showed that selected miRNAs also 
target important genes in coagulation and haemostasis. The miRNA, miR-494, downregulates 
Protein S (PS) mRNA levels by binding to the 3’UTR sequence of PROS1 mRNA transcript. 
Further study demonstrated that some coagulation factors without predicted miR-494 binding 
sites in their 3’UTR sequences showed significant changes in their mRNA levels, including 
plasminogen (PLG), tissue factor (F3) and C4BPα (C4BPA). It is possible that miR-494 directly 
targets transcriptional activators or repressors to indirectly regulate the expression of those 
coagulation factors lacking predicted miR-494 binding sites. This current study hypothesised 
that miR-494 has an important role in regulating coagulation pathways and haemostasis by 
targeting multiple coagulation factor genes via direct and indirect mechanisms. HuH-7 cells 
were transfected with miR-494 for 48h and 72h followed by mRNA and protein analysis. Direct 
interaction between miR-494 and transcription factor 3’UTRs (JUN, SP1 and STAT5B 3’UTRs) 
was determined using dual-luciferase reporter assays. The mRNA and protein levels of PS 
and PLG was significantly downregulated, and the C4BPA mRNA and protein levels were 
upregulated with the presence of miR-494. Moreover, the protein level of tissue factor (TF) 
was decreased at 72h post-transfection but no changes were found in its mRNA levels. 
Computational analyses showed that predicted miR-494 binding sites were found in the JUN, 
SP1 and STAT5B 3’UTRs. Dual luciferase reporter assay confirmed the presence of functional 
miR-494 binding sites in the 3’UTR sequence of SP1 and STAT5B. The SP1 and STAT5B 
mRNA levels were significantly downregulated with the presence of miR-494 but no change 
was observed for the JUN mRNA levels. Computational analysis showed that a predicted Sp1 
binding site was found in the promoter region of human PLG gene. A report by Gutierrez-
Fernandez et. al. (2007) suggested that Sp1 acts as a transcriptional activator in the murine 
PLG promoter. These suggested that miR-494 may indirectly downregulate PLG expression 
by targeting Sp1. Taken together, miR-494 directly downregulates PS expression, and 
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indirectly downregulates PLG expression through Sp1 repression and upregulates C4BPA 



















The average life-expectancy together with the world population has increased dramatically 
during the 20th century (Hunter and Fineberg, 2014). Non-communicable diseases, including 
cancer, chronic respiratory disease and liver disease, are major contributors to the fatal burden 
and disability worldwide, with cardiovascular disease being the leading cause of death (GBD 
2013 Mortality and Causes of Death Collaborators, 2015). Cardiovascular diseases, such as 
ischaemic stroke and venous thromboembolism, are caused by imbalances in haemostasis 
(blood coagulation) leading to thrombosis, which is the formation of a blood clot (thrombus) in 
the blood vessel obstructing blood flow through the circulation. 
 
Platelet activation and activation of the coagulation cascade are complex haemostatic 
mechanisms that are tightly regulated by different coagulation activators and inhibitors. Under 
normal physiological conditions, haemostasis acts in response to vascular injury to prevent 
unnecessary blood loss from damaged vessels. Thrombosis prevention, however, involves 
careful control of preventing excessive clot formation and clot dissolution. Increasingly, 
evidence suggests additional layers of complexity in the regulation of blood clotting and 




Haemostasis is a normal physiological response for preventing blood loss from injured blood 
vessels and repairing the damaged endothelium. Aberrant blood clotting and disturbed platelet 
activity can cause uncontrolled blood loss leading to severe haemorrhage or increased clotting 
resulting in thrombosis. Haemostasis consists of two major phases, primary (platelet 
activation) and secondary (coagulation cascade) haemostasis. Platelets are involved in both 
phases of the haematological response.  
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Platelets are blood circulating anucleate discoid cells (~4μm diameter and ~1μm thick) 
responsible for blood clot formation. They are generated from the cytoplasm of their precursor 
cells, mature megakaryocytes, which are enormous cells (50-100μm in diameter) with large 
nuclei produced in the bone marrow. Platelets are continuously replaced and the average 
normal platelet lifespan is about 9 to 12 days (Martini and Nath, 2009). The formation of 
platelets and the rate of megakaryocyte activity are stimulated by (1) thrombopoietin, a peptide 
hormone generated in the kidneys; (2) interleukin-6, a hormone that stimulates platelet 
formation; and (3) multi-CSF, a cytokine that promotes the growth of megakaryocytes. 
Platelets have three important glycoprotein receptors, glycoprotein (GP) Ib-V-IX complex, 
GPVI and GPIIb/IIIa. These receptors are responsible for the detection of exposed 
subendothelial matrix to activate platelets in response to endothelial injury (Clemetson, 2012).  
 
 
1.2.1 Primary haemostasis: Platelet Activation and aggregation 
Platelet activation and aggregation constitutes primary haemostasis (Figure 1.1). The first 
phase of primary haemostasis, also known as adhesion, acts to slow down moving platelets 
in the plasma which enables interaction with the exposed matrix. The major molecular 
response to this process includes Von Willebrand Factor (VWF) and the platelet receptors – 
GPIb-V-IX, GPIIb-IIIa and GPVI (Adams and Bird, 2009). VWF is another important 
component in haemostasis, which participates in platelet adhesion, aggregation and 
coagulation. VWF is a large multimeric glycoprotein consisting 2-80 subunits linked by 
disulphide bridges. The larger multimeric glycoproteins are stored in Weibel-Palade bodies 
(endothelial cells) or alpha granules (platelets). The smaller multimeric glycoproteins are 
constitutively secreted by megakaryocytes and endothelial cells. In the coagulation cascade, 
binding sites for VWF are present in collagen, GPIb, GPIIb/IIIa and Factor VIII. Multimeric 
VWFs enhance platelet aggregation and the large VWF multimer is regulated through 
continuous cleavage by A Disintegrin and Metalloproteinase with a ThromboSpondin Type 1 
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motif, member 13 (ADAMTS13); an important process in preventing aberrant thrombosis 
(Sadler, 1998).  
 
In adhesion, VWF circulating in plasma binds to specific sites on the exposed matrix. This 
allows the GPIb-V-IX receptor complex on platelets to interact with the A1 domains within 
VWF, inducing platelet activation (Ruggeri, 1997; Ruggeri, 2003). This is achieved through 
platelet GPVI receptors binding to collagen and the direct interaction to the exposed matrix 
(Sugiyama et. al., 1987). Activated platelets then release a coagulation factor, thrombin, which 
has an important role in secondary haemostasis. In addition, activated platelets also secrete 
multiple molecules, including thromboxane A2 (TXA2); fibrinogen, VWF and Factor V (FV) from 
alpha granules; and adenosine diphosphate (ADP) from dense granules, to recruit more 
platelets and accelerate the aggregation process (Weiss, 1975; Hamberg et. al., 1975; 
Harrison and Cramer, 1993). 
 
Platelet aggregation constitutes an important step in platelet plug formation and haemostasis. 
The release of TXA2, and molecules from alpha and dense granules creates a positive 
feedback loop to activate other platelets nearby; the ADP molecules bind to both P2Y1 and 
P2Y12 receptors and the TXA2 molecules bind to thromboxane receptors (TPα) on the platelet 
membrane (Cattaneo et. al., 2002). Thrombin also binds to proteinase-activated receptor 
(PAR) 1 and PAR4 receptors on the platelet membrane to activate other platelets 
(Ramakrishnan et. al., 2001). Platelet activation induces morphological changes, from 
biconvex discoid to irregular with multiple filopodial extensions caused by increased 
intracellular calcium ions. The morphological change in activated platelets increases their 
ability to interact and adhere to neighbouring platelets due to the increased surface area 
(Clemetson, 2012). During aggregation, platelet activation changes the GPIIb/IIIa receptors 
from an inactive to active state. Fibrinogen and VWF act as bridges between two GPIIb/IIIa 
receptors on neighbouring activated platelets. The interaction between fibrinogen, VWF and 
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GPIIb/IIIa receptors, as well as the shape changes in activated platelets, results in the 
formation of a stable platelet plug (Bennett, 2005). 
 
 
Figure 1.1. Factors and receptors involved in platelet activation (Pignone and Williams, 2010). 
 
1.2.2 Secondary haemostasis: coagulation cascade  
The coagulation cascade was first described in 1964 (Davie and Ratnoff, 1964; Macfarlane, 
1964), which highlighted the stepwise activation of zymogens that ultimately results in the 
conversion of fibrinogen into fibrin to form a clot. This traditional model indicated that these 
series of reactions followed either intrinsic (initiated by contact system) or extrinsic (initiated 
by tissue factor) pathway. These two pathways result in the activation of Factor X (FX) and 
the conversion of prothrombin into thrombin. However, this traditional model is no longer 
deemed to be the most accurate model in physiology. Ø sterud and Raparort (1977) argued 
that the intrinsic and extrinsic pathways of the coagulation cascade are not separate because 
the TF/FVIIa complex is able to activate Factor IX (FIX) in the intrinsic pathway. Clinical studies 
have found that patients with Factor XII (FXII) deficiency do not suffer severe haemorrhage in 
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comparison to patients with FIX deficiency (Hoffbrand and Pettit, 1993). As such, the 
coagulation cascade is a far more complex process than the simple pathway that was 
originally described. More anticoagulant proteins, such as Protein C and tissue factor pathway 
inhibitor (TFPI), and the fibrinolysis pathway were discovered after the description of the 
traditional model. Currently, the contemporary model of coagulation cascade includes 
initiation, amplification and propagation phases. Compared to the traditional model, the 
contemporary model suggests that the coagulation cascade is initiated by tissue factor (TF) 
and acts to further enhance the effects of TF in the amplification phase (Camerer et. al., 1996). 
 
1.2.2.1 Initiation and amplification phases 
TF is a transmembrane glycoprotein and a member of the class II cytokine receptor family. It 
is constitutively expressed in the vascular adventitia and membrane exposed after vessel 
injury. It is also highly expressed in heart, lungs, kidneys and brain. It has important roles in 
inflammation, apoptosis, embryonic development, cell migration and coagulation. The 
coagulation cascade is initiated by the release of TF from the vascular adventitia, known as 
initiation phase or TF pathway or extrinsic pathway (Figure 1.2). TF also functions as a 
cofactor for Factor VII (FVII) to activate FVII and cause the TF/FVIIa complex formation. The 
TF/VIIa complex activates FX. FXa and thrombin activate FV to cause the formation of 
prothrombinase complex through the interaction of FXa and FVa (Monkovict and Tracy, 1990; 
Schuijt et. al., 2013). The prothrombinase complex activates prothrombin, however, this can 
only produce small amounts of thrombin. Compared to the initiation phase, the amplification 
phase, which is also known as contact activation or intrinsic pathway, can increase FXa 
production by 50 to 100 times to accelerate thrombin production (Lawson and Mann, 1991; 
Ahmad et. al., 1992; Mann et. al., 1992). In the amplification phase, the TF/FVIIa complex 
activates Factor IX (FIX); while thrombin activates FV, FIX and Factor VIII (FVIII). The 
formation of FIXa/FVIIIa complex by the binding of FIXa and FVIIIa activates FX and produces 
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more thrombin (Camerer et. al., 1996). These activated coagulation factors create a positive 
feedback loop and results in a rapid generation of thrombin and platelet activation.  
 
 
Figure 1.2. Coagulation cascade and its regulatory proteins (Long Road Graphics Inc, 2012). 
 
1.2.2.2 Propagation phase 
The propagation phase, also known as the final common pathway, is the last phase of the 
coagulation cascade for blood clot formation. Fibrinogen is a hexamer composed of two sets 
of three polypeptides (Aα, Bβ and γ), encoded by FGA, FGB and FGG genes, respectively, 
and linked together by disulphide bonds (Fish and Neerman-Arbez, 2012). It is the precursor 
of fibrin, and a key component of blood clot formation by acting as bridges for platelets. The 
efficiency of blood clot depends on optimum thrombin generation by (1) activated platelets; (2) 
other essential components in coagulation, such as calcium; (3) coagulation factors involved 
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in the amplification phase; (4) and the prothrombinase complex. The result of the “thrombin 
burst” generated from the amplification phase results in a large amount of fibrinogen converted 
into fibrin and the activation of Factor XIII (FXIII). An effective, stable clot requires coalescing 
a large amount of fibrin monomers to form fibrin polymers, which are generated from the 
interactions between cross-linked fibrin polymers and active FXIII (FXIIIa). The clot stability 
can be affected by various factors, including pH, calcium concentration, thrombin 




Fibrinolysis is essential for removing the blood clot produced by activated coagulation (Figure 
1.2). It is highly regulated to ensure haemostasis is maintained. Plasmin is activated by 
plasminogen, a circulating proenzyme, which is activated by either tissue-type plasminogen 
activator (t-PA) or urokinase-type plasminogen activator (u-PA) (Hoylaerts et. al., 1982). 
These two serine proteases have a very short half-life because of high concentration of 
plasminogen activator inhibitor-1 (PAI-1), an inhibitor of t-PA and u-PA, presented in the 
circulation. t-PA is synthesised and secreted by endothelial cells; and u-PA is secreted from 
various cell types, such as monocytes, macrophages and urinary epithelium. The activation of 
plasmin results in cleavage of cross-linked fibrin and production of fibrin degradation products, 
such as, D-dimer. In addition to PAI-1, alpha 2 antiplasmin (α2AP) and Thrombin Activatable 
Fibrinolysis Inhibitor (TAFI) also negatively regulate the fibrinolysis. α2AP inhibits plasmin 
under normal physiological conditions, however, α2AP is unable to bind to plasmin while 
plasmin is bound to fibrin in fibrinolysis. Moreover, thrombin activates TAFI to protect the clot 
from being removed by plasmin. TAFI downregulates fibrinolysis by removing an important 
binding site in plasminogen, fibrin C-terminal residues, and reduces the effectiveness of 




1.2.3 Regulation of coagulation cascade  
Regulation of the coagulation cascade is essential for preventing excessive thrombin and fibrin 
production. At least four major regulatory proteins have been described in the coagulation 
cascade, including antithrombin, TFPI, Protein C and Protein S (PS) (Figure 1.2).  
 
1.2.3.1 Anticoagulation factors 
Antithrombin, also known as antithrombin III, is a serine protease inhibitor and is an important 
inhibitor of coagulation. It is constitutively activated to degrade multiple procoagulation factors, 
including thrombin, FVIIa, FIXa, FXa and FXIa. Another inhibitor in the coagulation cascade 
is TFPI, a single chain polypeptide. TFPI is an endogenous inhibitor of the coagulation 
cascade, which inactivates both the TF/FVIIa complex and FXa (Sandset and Abildgaard, 
1991). It circulates in the blood stream by binding to low-density lipoprotein, and is generated 
by endothelium and platelets. Therefore, antithrombin and TFPI are the regulators in 
coagulation and prevent the development of thrombosis (Adams and Bird, 2009). 
 
1.2.3.2 Anticoagulation Protein C Pathway 
Anticoagulation Protein C pathway is important for regulating coagulation and preventing 
thrombosis. Thrombin is activated through a series of reactions in the initiation and 
amplification phases of coagulation (Figure 1.3I). Thrombin binds to epidermal growth factor 
(EGF) domains 5 and 6 of thrombomodulin (TM). This allows the interaction between 
endothelial Protein C receptor (EPCR) and Protein C. EPCR binds to the Gla domain of 
Protein C and stimulates Protein C activation (APC) (Figure 1.3II). Protein S (PS) acts as a 
cofactor of APC and degrades FVa and by cleaving FVa heavy chains, where FVIIIa is 
degraded by APC through the stimulation of FV and PS (Figure 1.3III) (Dahlback, 1991; 






Figure 1.3. The anticoagulation Protein C pathway (Dahlback and Villoutreix, 2005).  
 
Protein S (PS), encoded by PROS1 gene, is a non-enzymatic vitamin K-dependent plasma 
protein and is primarily synthesised by hepatocytes (Fair and Marlar, 1986). It acts as a 
cofactor of APC to degrade FVa and FVIIIa, and inhibit thrombin formation (Figure 1.3III) (Fay 
and Walker, 1989). PS is a mosaic protein with four different functional domains, including a 
gamma-carboxyglutamic acid (GLA), a thrombin-sensitive region (TSR), four epidermal 
growth factor-like (EGF-like) modules and a sex hormone binding globulin (SHBG)-like domain 
(Vehar and Davie, 1980).  
 
 
C4b-binding protein (C4BP), encoded by C4BPA and C4BPB genes, is a large, spider-like 
structured glycoprotein which contains seven α chains, an unique β chain and a central core 
to hold these chains together by disulphide bonds. Each α chain consists of eight complement 
control protein (CCP) domains, whereas the β chain contains three CCP domains and a PS 
binding site (Goldsby et. al., 2000). Approximately 30% to 40% of PS in plasma is free 
circulating PS, and the remaining PS is bound to the C4BP β-chain to generate the C4BP-PS 
complex (Goldsby et. al., 2000). When in the complex with C4BP, PS is not functional in the 
I Activation and propagation of coagulation II Activation of Protein C by T-TM-ERCR 
III Degradation of FVIIIa and FVa by APC 
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anticoagulation Protein C pathway and loses its ability to interact with tyrosine kinase 
receptors (Evenas et. al., 2000). However, the C4BP-PS complex remains functional in the 
complement system because the α-chains are not affected by PS. Therefore, a very strong 
interaction between PS and the β-chain of C4BP allows indirect regulation of the coagulation 




Figure 1.4. The C4BP and PS interaction regulates coagulation (Dahlback and Villoutreix, 2005). C4b-
binding protein (C4BP) contains seven α chains and an unique β chain. Protein S (PS) binds to C4BP 
β-chain and causes loss of PS function. Therefore, C4BP can indirectly regulate the coagulation 




















1.3 Protein S deficiency 
PS deficiency is divided into hereditary and acquired PS deficiency. Hereditary PS deficiency 
is a serious autosomal dominant disorder caused by mutations in the PROS1 gene. It can be 
categorised into three types: patients with type I PS deficiency have reduced PS activity with 
low total and free PS levels, type II patients have reduced PS activity with normal total and 
free PS levels; and type III patients have both low PS activity and low free PS levels but normal 
total PS levels (Bertina, 1990). Approximately 200 different PROS1 mutations have been 
characterised (Garcia de Frutos et. al., 2007). Using copy number variation analysis, Pintao 
et al. (2009) reported that 6 out of 18 (33%) probands with PS deficiency had duplications or 
deletions in the PROS1 gene. From these 6 cases, 3 probands with type I PS deficiency were 
found to have complete deletion of PROS1 gene. Partial deletions of PROS1 from exons 4 to 
9 and exons 9 to 11 were detected in probands with type I and type III deficiency, respectively. 
Genetic analysis of the family shown thrombotic conditions over three generations shows that 
a novel nonsense mutation was identified in the PROS1 gene (Cho et. al., 2012). A transition 
(AAG  TAG) detected in the exon 10 of the PROS1 gene. The nonsense mutation in the 
PROS1 gene causes vascular access thrombosis (Cho et. al., 2012). 
 
Individuals with no alterations of PROS1 gene can cause acquire PS deficiency under various 
conditions, including chronic inflammation, vitamin-K deficiency, liver diseases and especially 
increased circulating oestrogen levels during pregnancy and contraceptive pill use (Ten Kate 
and Van Der Meer, 2008). Both hereditary and acquired PS deficiency are associated with a 
significant increased risk of venous thrombosis (Pintao et. al., 2009; Castoldi et. al., 2010). 







1.4 Micro-ribonucleic acids: 
Micro-ribonucleic acids (miRNAs) are small regulatory, non-coding RNAs, ~22 -25 nucleotides 
in length, which regulate gene expression by binding to the 3’ untranslated region (UTR) 
sequence of target mRNAs to cause mRNA degradation or repress mRNA translation (Teruel-
Montoya et. al., 2015). The first miRNA, lin-4, was discovered in Caenorhabditis elegans in 
1993 (Lee et. al., 1993). The expression of lin-4 was found to be induced at the beginning of 
the larval development stages of C. elegans and occurred in association with the 
downregulation of the lin-14 gene, however, lin-4 did not code for any functional protein (Lee 
et. al., 1993). Through further investigation, Lee et al. (1993) found that lin-4 bound via 
complementary base pairing at multiple locations within the 3’UTR of lin-14 gene leading to 
inhibition of lin-14 mRNA and protein expression. This discovery demonstrated a novel 
posttranscriptional gene regulation mechanism that has since revolutionised the study of 
functional non-coding RNAs. miRNAs have been reported to play important roles in cell 
growth, apoptosis, gene regulation and the maintenance of cell differentiation. Recently, 
several miRNAs have been reported to target genes that regulate different stages in the 
coagulation system (Teruel-Montoya et. al., 2015). Research from our laboratory have 
reported that the miRNA, miR-494, directly targets the anticoagulant, Protein S, and regulates 
the expression of different coagulation factors, postulating an important role for miR-494 in the 
coagulation (Dr. Jasmine Tay, personal communication).  
 
1.4.1 miRNA biogenesis 
miRNA genes are transcribed from DNA by RNA polymerase II to form primary miRNAs (pri-
miRNAs), which are about 60-100 nt in length (Figure 1.5) (Lee et. al., 2002; Lee et. al., 2004). 
The pri-miRNA transcripts are subsequently processed by a number of enzymes, first by the 
Drosha complex, a nucleic RNAse III endonuclease – along with DiGeorge critical region 8 
(DGCR8), which is a Drosha cofactor. DGCR8 is a double-stranded RNA binding domain 
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protein with the function of cleaving longer pri-miRNAs into short single hairpin precursor-
miRNAs (pre-miRNA) (Lee et. al., 2003; Han et. al., 2004). Then, pre-miRNAs are exported 
out of the nucleus by exportin-5 and Ran-GTP for further processing (Rui Yi et. al., 2003).  
 
Figure 1.5. miRNA biogenesis and regulation of its target genes (Kapinas and Delany, 2011).  
 
Once in the cytoplasm, pre-miRNAs are cleaved by the Dicer enzyme complex, a cytoplasmic 
RNAse III, which removes the loop structure of pre-miRNA molecules to generate double 
stranded miRNAs ~22 nt in length (Carmell and Hannon, 2004). Mature miRNAs are then 
transferred by the Dicer complex to the RNA-induced silencing complex (RISC) which consists 
of Argonaute proteins (Ago1, Ago2, Ago3 and Ago4). RISC is a key component of miRNA and 
small interfering RNA (siRNA) biogenesis, as well as initiating gene silencing to protect cells 
from viral infections. Argonaute proteins in RISC unwind the miRNA duplexes to form a mature 
single-stranded miRNA products (Landthaler et. al., 2008). The passenger strand will usually 
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be degraded by RISC. After the formation of mature miRNA in RISC, the RISC incorporated 
miRNA causes mRNA degradation or translational repression by binding to the 3’UTR 
sequence of miRNA’s target genes (Kapinas and Delany, 2011).  
 
1.4.2 miRNA target recognition 
miRNAs are able to recognise their targets through total and partial complementarity. Target 
recognition is highly dependent on base-pairing between the miRNA seed region, which is 
made up of 2-8 nucleotides from the 5’-end of the miRNA, and the target mRNA to repress 
protein expression. miRNAs, which bind with partial complementarity, accelerate the 
processes of deadenylation and cause mRNA decapping leading to general translational 
repression (Eulalio et. al., 2009). A perfect complementary miRNA-mRNA interaction results 
in the destabilisation of the target mRNA where it is cleaved by Ago proteins in RISC. Different 
seed binding types affect the functional capacity of miRNAs. The seed types are divided into 
three main groups: 5’ dominant seed, 5’-dominant canonical and 3’ compensatory (Figure 1.6). 
In 5’-dominant seed sites, minimal additional base pair with canonical seed sequence is 
initially described as strong target regulation. With 5’-dominant canonical sites, the 5’ and 3’ 
ends of miRNAs can pair well to their targets. The supplementary 3’-base pairing in the 5’-
dominant canonical site allows increased binding effectiveness. The 3’-compensatory sites, 
which contain disrupted seed sequence with compensatory 3’ base pairing (usually more than 





Figure 1.6. Three types of miRNA binding sites (Carroll et. al., 2014). Minimal additional base pair with 
seed sequence in 5’- dominant seed binding sites. In 5’-dominant canonical binding site, the binding 
effectiveness increases due to the supplementary 3’ base pairing. The 3’-compensatory binding sites 
consist of disrupted seed binding leading to insufficient target regulation. 
 
A number of bioinformatic algorithms to predict miRNA-mRNA binding have been developed, 
which have been very useful in determining potential functions of different miRNAs by looking 
at the identities of their target mRNAs. The algorithms for predicting miRNA target sites 
incorporate various parameters, such as base-pairing complementarity, binding site 
accessibility and thermodynamic stability of the predicted interaction (Table 1.1). The most 
commonly used prediction algorithms (freely available online) are microRNA.org, TargetScan, 
RegRNA, DIANA microT and PicTar. TargetScan predicts the miRNA binding sites by 
searching 8mer (the seed and position 8 which followed by an A) and 7mer (the seed and 
position 8; and seed followed by an A) sites which exactly match the seed region of each 
miRNAs (Lewis et. al., 2005). Apart from the seed region, microRNA.org includes 
experimentally validated targets for those miRNAs that do not contain perfect seed matches; 
and includes other approaches introduced 3’-compensatory matches or the seed and 3’ match 
rules (Betel et. al., 2008). RegRNA collects data from miRBase and integrates it with the 
miRanda algorithm to detect miRNA binding sites in the target sequence (Chang et. al., 2013). 
miRanda is one of the prediction tools used in microRNA.org, it enhances sequence 
complementarity by using multiple position-specific rules from different experiments and 
evolutionary conservation (John et. al., 2004). 
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Table 1.1. The features of different available prediction algorithms (Liu et. al., 2014). Letters in species indicate prediction for human (H), mouse (M), rat (R), fly (F), 
worm (W), dog (D), chicken (C), and any species (A). 
Algorithm Region Scanned 
Species 
Conservation Species Brief Description of the Prediction Method Download/ Web server 
miRanda 3’UTR Yes 
H, M, R, F, 
W 
 
Predict targets based on rules: (i) sequence complementarity; (ii) binding 
energy; and (iii) evolutionary conservation. 
 
http://www.microrna.org 
mirSVR No restriction Yes H, M, R, F, 
W 
To score and rank miRanda-predicted miRNA target sites with a supervised 
vector regression model (SVR) for features including secondary structure 
accessibility of the site and conservation. 
 
http://www.microrna.org 
PicTar 3’UTR Yes H, M, R, F, 
W 
Filter alignments according to the thermodynamic stability, then score and rank 




TargetScan 7mer and 8mer 
sites, and 
ORF 
Yes  H, M, R, D, 
C 
Predict targets by searching for the presence of conserved 8mer and 7mer 
sites that match the seed region. Predictions are ranked by a combinatorial 
score based on site number, site type, and site context. 
 
http://www.targetscan.org/ 
TargetScanS 3’UTR Yes H, M, R, D, 
C 
Predict targets that have a conserved 6-nt seed match flanked by either a m8 




RNA22 No restriction No A Use the patterns discovered from the known mature miRNAs for predicting 




EIMMo 8mer sites Yes A A Bayesian method infers miRNA target sites by explicitly model the evolution 




PITA 3’UTR Yes H, M, W, F Predict miRNA targets using a nonparameter model that computes the 
difference between the free energy gained from the formation of the miRNA-
target duplex and the energetic cost of unpairing the target to make it 




RNAhybird 3’UTR and 
coding 
sequence 
No A A tool to identify mRNA secondary structure and energetically favourable 





DIANA microT 3’UTR and 
coding DNA 
sequence (CDS) 
No H, M The fifth version of microT algorithm which is specifically trained on a positive 
and negative set of miRNA recognition elements located in both the 3’-UTR 
and Coding DNA Sequence (CDS) region. The conserved and nonconserved 




miRmap 3’UTR Yes A Predicting targets by taking into account of probabilities, base pairing, target 




1.4.3 miRNA regulates gene expression via an indirect mechanism 
Evidence suggests that the regulation of miRNAs is not restricted to downregulating gene 
expression but also mediate upregulation of gene expression. miRNAs mediate upregulation 
of  gene expression through targeting transcription factors, such as STAT5B and XBPI. A 
report by Williams et al. (2012) demonstrated that miR-200a in human myometrial cells directly 
downregulates signal transducer and activator of transcription (STAT) 5B, which is a 
transcriptional repressor of 20α-hydroxsteroid dehydrogenase (20α-HSD). These results 
suggest that miR-200a indirectly enhances 20α-HSD expression through directly supressing 
STAT5B expression.  Duan et al. (2015b) reported that a significant increase of miR-214 was 
identified in heart failure patients. miR-214 overexpression reduces the XBPI expression, a 
key transcription factor of unfolded protein response, by binding to its 3’UTR sequence.  The 
XBPI downregulation causes regulation of other gene expression, leading to decreased cell 
migration and angiogenesis. In contrast, miRNAs indirectly downregulates gene expression 
by targeting transcriptional activator of a gene. Garzon et al. (2009) reported that miR-29b 
regulates the expression of DNA (cytosine-5)-methyltransferase 1 (DNMT1) without miR-29b 
binding sites in the 3’UTR sequence of DNMT1, however, miR-29b directly downregulates a 
transcriptional activator of DNMT1 - specificity protein 1 (SP1) - to indirectly repress DNMT1 
expression. These studies showed that miRNAs can indirectly up- or downregulate gene 
expression by targeting transcriptional activators or repressors. 
 
1.4.4 Functional roles of miRNAs 
Krek et al. (2005) estimated that approximately 30% of protein coding genes are regulated by 
miRNAs. According to the latest edition of miRbase (released on 21 June 2014), more than 
2,500 mature miRNAs in humans have been discovered (Manchester, 2015). Many miRNAs 
have been demonstrated to play important roles in the regulation of key cellular processes, 
such as apoptosis and cell proliferation. Furthermore, miRNAs have also been implicated in 
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the pathophysiology of various cancers. In contrast, miRNA’s role in coagulation and 
haemostasis is still poorly characterised. 
 
 
1.4.4.1 miRNAs in haemostasis and coagulation  
Recent studies have identified several miRNAs that directly target important genes in 
coagulation and haemostasis (Figure 1.7). Multiple miRNAs have been ascribed roles in 
regulating the coagulation cascade by targeting the major procoagulants, fibrinogen and tissue 
factor, as well as Factor XI (FXI). Recent studies showed that the miR-17-92 cluster and miR-
223 downregulates the expression of TF and regulates the coagulation cascade (Li et. al., 
2014b; Li et. al., 2014c). The expression of TF, encoded by the F3 gene, is a critical regulatory 
point of the coagulation cascade. Moreover, miR-223 directly downregulates TF expression 
(Li et. al., 2014b).  Overexpression of miR-223 partially reduces the effects of increased TF 
procoagulant activity induced by tumour necrosis factor α (TNF-α) (Li et. al., 2014b). The miR-
17-92 cluster, miR-19a, miR-19b and miR-20a, involve in regulating TF expression. Increased 
miR-19b expression in the plasma of unstable angina patients directly suppresses the 
expression of TF (Li et. al., 2014c). Furthermore, miR-106b and miR-20a share the same 
binding sites in the 3’UTR sequences of TF, where miR-19b is binding to a different site. These 
miRNAs downregulate mRNA and protein expression of TF in both breast cancer and 
monocytic leukaemia cells (Teruel et. al., 2011). In addition, miR-19 and miR-19a directly 
target TF and cause cell migration and carcinogenesis in the breast cancer cell line (MCF-7) 
and colon cancer cells respectively (Zhang et. al., 2011; Yu et. al., 2013a). An additional study 
reported that TF expression can be regulated by both miR-20b and Erk1/2 pathway 
independently (Yu et. al., 2013b). Although these three studies did not discuss the impacts of 
TF expression in haemostasis, these miRNAs may still have an important role in inhibiting 




Fibrinogen and Factor XI (FXI) are also one of the coagulation factors which are targeted by 
miRNAs. miR-409-3p directly targets FGB mRNA, which is β-polypeptide chain of fibrinogen; 
and miR-29c specifically downregulates one of the five fibrinogen transcripts (FGA-αE) (Fort 
et. al., 2010). miR-29 family members (a, b or c) were able to significantly downregulate the 
expression of all five transcripts of fibrinogen (FGA, FGA-αE, FGB, FGG and FGG’) in HuH-7 
cells, which was postulated to occur via direct 3’UTR binding of miR-29 or indirectly through 
miR-29 targeting of other undetermined regulators (Fort et. al., 2010). Hatziapostolou et al. 
(2011) identified that the transcription factor hepatocyte nuclear factor 4α (HNF) contains 
functional binding sites for miR-29a and miR-29b, which can explain the indirect mechanism 
of fibrinogen gene regulation by miR-29a and miR-29b. miR-181a-5p expression was shown 
to be inversely correlated with FXI levels in human livers. In addition, FXI-3’UTR was found to 
contain functional miR-181a-5p binding sites where miR-181a-5p was able to downregulate 
FXI-3’UTR-dependent luciferase activity in HepG2 liver cells (Salloum-Asfar et. al., 2014).  
 
 
Figure 1.7. The regulation of haemostasis and coagulation by miRNAs (Teruel-Montoya et. al., 2015). 





1.5 Micro-ribonucleic acid 494: 
The miRNA, miR-494 (hsa-miR-494-3p), is located on chromosome 14 (14q32.31) and related 
to the miR-154 family that consists of 18 members. Members of the miR-154 family, including 
miR-494, have been identified to be deregulated in cystic fibrosis (Megiorni et. al., 2011). 
Studies have shown that miR-494 expression is reduced in different carcinoma cells, such as 
oral cancer and esophageal squamous cell carcinoma, as well as in skeletal muscle cells 
during endurance exercise (Yamamoto et. al., 2012; Yamanaka et. al., 2012; Liu et. al., 2012). 
In addition, miR-494 expression has been reported to be increased in chronic heart failure, 
hepatocellular carcinoma, breast cancer and glioblastoma cells (Mohnle et. al., 2014; Sun et. 
al., 2014; Chuang et. al., 2015; Li et. al., 2015). Taken together, these studies demonstrate 
multiple roles for miR-494 in promoting carcinogenesis and other diseases.  
 
 
1.5.1 Known functions of miR-494 
Many studies investigating the function of miR-494 in various cell types have identified several 
gene targets directly inhibited by miR-494 to regulate numerous cellular processes. These 
include processes, such as apoptosis, cell cycle progression and kinase signalling, as well as 
progression of various cancers (Table 1.3). 
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Table 1.2. Published studies of the miR-494 functions. 






Cell types used Characterised miR-494 function References 
Cause cancer Ten methylcytosine 
dioxygenase 
TET1 Human hepatocellular 
carcinoma cells 
miR-494 suppresses TET1 gene expression to inactivate gene transcription of 
several invasion-suppressor miRNAs leading to tumour vascular invasion. 
(Chuang et. al., 
2015) 
p190B RhoGAP  p190B Human glioma cells miR-494 directly downregulates RhoA regulator p190B to increase the expression 
of EGFR and MMP-2, and promotes invasion. 




PTEN Human bronchial 
epithelial cells 
In anti-BPDE-induced transformed cells, overexpressed miR-494 negatively 
regulates PTEN expression so miR-494 acts as a micro-oncogene in 
carcinogenesis. 
(Liu et. al., 2010) 
Murine breast cancer 
cells 
miR-494 activates Akt, mTOR and NF-KB and inhibits MMP expression by 
targeting PTEN. Active PTEN/AKT pathway enhances tumour growth and 
metastasis.  
(Liu et. al., 2012) 
Human colorectal 
carcinoma cells 
Increased expression of miR-494 in human colorectal carcinoma cells leads to 
direct reduction of PTEN expression and promotes cell migration and invasion. 
(Sun et. al., 2014) 
EBV-infected 
lymphoma of nasal 
natural killer cells 
miR-494 directly inhibits PTEN to activate AKT pathway. miR-494/PTEN/AKT 
pathway is critical in the pathogenesis of nasal natural killer cell lymphoma. 




miR-494 promotes invasion, proliferation, migration and prevents apoptosis by 
downregulating PTEN expression through PTEN/AKT pathway. 
(Li et. al., 2015) 
Human NSCLC tissue Overexpressed miR-494 directly downregulates PTEN expression and causes 
non-small cell lung cancer (NSCLC). 











miR-494 directly downregulates GALNT7 and CDK16 to inhibit the 
nasopharyngeal carcinoma tumourigenesis. 






transforming gene 1 
PTTG1 Human Cervical 
carcinoma cells 
miR-494 inhibits the tumour metastasis of cervical cancer by directly 
downregulating PTTG1. 




VEGF Human mesenchymal 
stem cells 
Overexpression of miR-494 directly suppresses the VEGF expression and inhibits 
angiogenesis. 
(Chen et. al., 
2015c) 
Phosphorprotein 
enriched in diabetes 
PEA15 Human epithelial cells Downregulation of miR-494 mediated by AP1 increases BIM and PED 
expression. This causes inhibition of proliferation. 
(Romano et. al., 
2012) 
c-myc MYC Human gastric 
epithelial mucosa cells 
Decreased expression of miR-494 in gastric carcinoma cells results in increased 
expression of c-myc. miR-494 acts as an anti-oncogene in gastric carcinoma 
cells. 
(He et. al., 2014) 
Human pancreatic 
carcinoma 
miR-494 inhibits proliferation and invasion of pancreatic cancer by inhibiting the 
c-myc/SIRT1 positive feedback loop . 
(Liu et. al., 2015) 
Sirtuin 1 SIRT1 
Sybdecan 1 SDC1 Human 
medulloblastoma 
miR-494 regulates the MMP-9/SDC1 negative feedback loop by downregulating 
MMP-9 and SDC1. This regulatory loop has a significant impact on the tumour 
growth and angiogenesis. 











Cell types used Characterised miR-494 function References 
Inhibits 
tumourigenesis 
Homeobox A10 HOXA10 Human tongue 
squamous cells 
miR-494 directly downregulates HOXA10 expression and prevents cell 
proliferation in oral cancer, thus, miR-494 acts as a tumour suppressor miRNA. 
(Liborio-Kimura et. 
al., 2015) 
Forkhead box M1 FOXM1 Human pancreatic 
ductal adenocarcinoma 
cells 
miR-494 acts as a negative regulator of FOXM1 in pancreatic cells and causes 
inhibition of FOXM1/β-catenin signalling. This protects pancreatic 
tumourigenesis from inhibiting the promotors of proto-oncogenes.  
(Li et. al., 2014a) 
Dihydropyrimidine 
dehydrogenase 
DPYD Human colorectal 
carcinoma cells 
miR-494 acts as a tumour suppressor in colon cancer and increased the 
sensitivity of 5-Fu by downregulating DPYD expression. 
(Chai et. al., 2015) 
Insulin-like growth 
factor 2 mRNA-
binding protein 1 
IGF2BP1 Human lung cancer 
cells 
miR-494 downregulates the mRNA expression of IGF2BP1. IGF2BP1 
suppress IGF2 expression and inhibit cell proliferation. 




CXCR4 Human prostate 
epithelial cell line 
miR-494 suppresses proliferation, invasion and migration of prostate cancer 
via targeting CXCR4. 







PTEN Hearts of transgenic 
mice and human 
embryonic kidney cells 
miR-494 directly downregulates proapoptotic proteins (PTEN, ROCK1, 
CaMIIδ) and antiapoptotic proteins (FGFR2, LIF) and causes activation of Akt 
pathway to trigger cell apoptosis. 











HIF1A Human hepatic cells miR-494 causes increased HIF-1α and HO-1 expression via PI3K/Akt pathway 
to protect L02 cells against hypoxia-induced apoptosis. 
(Sun et. al., 2013) 
JunD proto-
oncogene 
JunD Human nucleus 
pulposus cells 
Downregulation of miR-494 causes upregulation of JunD and prevent nucleus 
pulposus cells from apoptosis.  








BAG-1 Huamn gastric cancer 
cells 
miR-494 directly suppresses BAG-1 expression to promote apoptosis and 
inhibit proliferation in BGC-823 cells. 
(Zhou et. al., 
2014) 
cleft lip and palate 
transmembrane 1-
like 
CLPTM1L Human esophageal 
squamous cell 
carcinoma  
miR-494 suppresses CLPTM1L expression by directly binding to its 3’UTR 
sequence. This causes apoptosis and inhibition of proliferation. 




KIT Human gastrointestinal 
stromal tumours cells 
In gastrointestinal stromal tumours cells, miR-494 acts as a negative regulator 
of KIT. This promotes apoptosis and inhibits cell growth and proliferation. 




ROCK1 Mouse osteoblast cells miR-494 reduces the expression of ROCK1 to inhibit cell proliferation. (Wang et. al., 
2010; Iwawaki et. 
al., 2015) 
Hearts of transgenic 
mice and human 
embryonic kidney cells 
miR-494 directly downregulates proapoptotic proteins (PTEN, ROCK1, 
CaMIIδ) and antiapoptotic proteins (FGFR2, LIF) and causes activation of Akt 
pathway to trigger cell apoptosis. 
Fibroblast growth 
factor receptor2 
FGFR2 Mouse osteoblast cells miR-494 reduces the expression of FGFR2 to inhibit cell proliferation. (Wang et. al., 
2010; Iwawaki et. 
al., 2015) 
Hearts of transgenic 
mice and human 
embryonic kidney cells 
miR-494 directly downregulates proapoptotic proteins (PTEN, ROCK1, 
CaMIIδ) and antiapoptotic proteins (FGFR2, LIF) and causes activation of Akt 
pathway to trigger cell apoptosis. 
Nucleolin NCL Human immoral cells miR-494 promotes apoptosis and inhibits cell proliferation by directly 
repressing the expression of NCL. 
(Tominaga et. al., 
2011) 
Secretagogin SCGN Human SCLC cell line miR-494 directly represses the expression of SCGN to promote apoptosis and 
prevent small cell lung cancer. 








Cell types used Characterised miR-494 function References 
Regulating 
cell cycle  
Cyclin-dependent 
kinase 6 
CDK6 Rat liver homogenates miR-494 regulates B[a]P-exposed cell cycle progression and G1/S transition by 
reducing the expression of CDK6 in primary murine bronchial epithelial.    




Overexpressed miR-494 downregulates CDK6 and CCND1 to arrest cell cycle at G1/S 
transition. 
(Olaru et. al., 
2011; Chen et. 
al., 2015c) Cyclin D1 CCND1 mesenchymal stem 
cells 







miR-494 represses the expression CDK4, CDK6, CCND1, CCNE2 and HDAC1, 
resulting in inhibiting cell cycle at G1/S transition. 
(Olaru et. al., 
2011) 
Cyclin E2 CCNE2 
Histone deacetylase 1 HDAC1 
Pituitary tumour-




miR-494 directly downregulates PLK1, CCNB1, CDC20, CDC2 PTTG1 and TOP2A 
expression and regulates the cell cycle at G2/M transition. 
(Yamanaka et. 
al., 2012) 
Topoisomerase II α TOP2A 
Polo-like kinase 1 PLK1 
Cyclin B1 CCNB1 
Cell-division cycle 20 CDC20 
Cell-division cycle 2 CDC2 
Mutated in Colorectal 
cancer 
MCC Mouse normal liver and 
tumour tissue 
miR-494 directly inhibits MCC expression, leading to downregulating two important 
regulators of G1/S transition, p27 and p21. This causes transformation in human liver 
cells. 
(Lim et. al., 
2014) 
Coagulation Protein S PROS1 Human liver carcinoma 
cells 
Increased circulating oestrogen levels results in upregulation of miR-494, and miR-
494 directly downregulate Protein S and causes Protein S deficiency.  
(Tay et. al., 
2013) 
Other Phosphatase and 
tensin homolog 
PTEN Human proximal 
tubular epithelial cells 
Increased expression of miR-494 in cells with cyclosporine A treatment lead to PTEN 
downregulation and causes tubular epithelial cell epithelial-mesenchymal transition. 
(Yuan et. al., 
2015) 
Mitochondrial 
transcription factor A 
TFAM Mouse myoblast cells Decreased expression of miR-494 during exercise or cell differentiation causes 
downregulation of TFAM and FOXJ3, leading to mitochondrial biogenesis. 
(Yamamoto et. 
al., 2012) 
Forkhead box j3 FOXJ3 
Protein deglycase DJ-
1 
PARK7 Mouse neuroblastoma 
cell and fibroblast 
DJ-1 protein expression is negatively regulated by miR-494 and causes oxidative 
stress and loss of dopaminergic neurons. 





CFTR Human airway 
epithelium 
TNF-α and IL-1β upregulates the miR-494 expression via transcriptional activator NF-
KB. miR-494 represses the mRNA expression of CFTR, therefore, miR-494 is an 
important regulator of homeostatic in respiratory tract. 
(Ramachandran 
et. al., 2013) 
Human bronchial 
epithelial  
Increased expression miR-494 represses CFTR expression to increase expression of 
∆F508 CFTR, which is the common CFTR mutants. 
(Oglesby et. al., 
2013) 
CF airway epithelium miR-494 and miR-101 downregulate CFTR expression and might explain the mutation 
of CFTR in CF patients. 
(Megiorni et. al., 
2011) 
Solute carrier family 
26, member 3 
SLC26A3 Human intestinal 
epithelial cells 
Downregulated in adenoma (DRA) protein is directly downregulated by miR-494 and 
causes inflammatory diarrheal diseases. 
(Anbazhagan 





miR-494 in cardiomyocytes directly downregulates CB1 receptor expression and acts 
as a biomarker of chronic heart failure. 




ATF3 Mouse kidney tissue miR-494 is upregulated in I/R-induced kidney injury and directly downregulates ATF3 
to cause severe kidney injury. 




1.5.1.1 miR-494 regulates different coagulation factors 
Recently, Tay et al. (2013) reported that functional miR-494 binding sites are present in the 
PROS1 mRNA-3’ UTR sequence. miR-494 downregulates the mRNA expression of PROS1 
by directly binding to these specific binding sites. The authors also demonstrated that 
oestrogen treatment of HuH-7 liver cells results in elevated miR-494 levels and is associated 
with decreased PS expression. The study showed a miRNA-mediated mechanism leading to 
PS deficiency under conditions of high circulating oestrogen levels. Further studies on the 
potential role for miR-494 in haemostasis was investigated by performing computational 
analyses of 40 coagulation genes using a number of miRNA binding site prediction tools – 
TargetScan, MicroRNA.org and RegRNA (Dr. Jasmine Tay, personal communication). These 
results showed that putative miR-494 binding sites are found in the 3’ UTR sequence of 
multiple coagulation factors, including thrombin (F2), PAI-1, PS (PROS1), thrombomodulin 
(TM), thrombospondin 1 (THBS1), Factor V (F5), FVIII (F8), FIX (F9), TFPI and Urokinase 
(PLAU) (Dr. Jasmine Tay, personal communication). Interestingly, research in the laboratory 
demonstrated that, with transfected miR-494 in HuH-7 cells, some coagulation factors without 
miR-494 binding sites in their 3’UTR sequences showed significant changes in their mRNA 
expression, including plasminogen (PLG), TF (F3) and C4BPα (C4BPA) (Figure 1.8). These 
results suggested that miR-494 is able to regulate the expression of different coagulation 
factors with or without miR-494 binding sites. It is possible that miR-494 directly targets 
transcriptional activators or repressors to indirectly regulate the expression of those 




Figure 1.8. The regulation of different coagulation factors by miR-494 (Tay et al. personal 
communication). miR-494 downregulates Protein S expression through a direct interaction between 
miR-494 and the 3’UTR sequence of Protein S. Moreover, miR-494 may indirectly regulates multiple 





1.5.3 miR-494 and transcription factors  
Internal laboratory computational analyses of miR-494 binding sites have identified more than 
9000 putative targets of miR-494 (unpublished results). Moreover, more than 100 transcription 
factor 3’UTRs contain one or multiple miR-494 binding sites, and key transcription factors AP1, 




Activator protein 1 (AP1) is an important tumorigenic transcription factor through regulating 
differential gene expression. Multiple AP1 family members, including c-Jun and junB, are 
involved in regulating cell apoptosis and proliferation. The activation of c-Jun and Jun NH2-
terminal kinase (JNK) prevents cell apoptosis and promotes proliferation, however, 
downregulation of JNK represses antiapoptotic genes and induces apoptosis through 
upregulation of junB (Jacobs-Helber et. al., 1998). Oeth et al. (1997) suggested that a distal 
and proximal AP1 binding sites were identified in the promoter region of tissue factor. On the 
other hand, evidence suggested that high circulating oestrogen levels results in 
downregulation of PROS1 gene expression. Suzuki et al. (2010) reported that high oestrogen 
levels in HepG2 cells results in downregulation of PROS1 through the Sp1-ERα interaction in 
the PROS1 promoter region. Moreover, Sp1 acts as a transcriptional activator of PS and 
plasminogen, with several functional Sp1 binding sites identified in the PROS1 and PLG 
promoter regions (de Wolf et. al., 2006; Gutierrez-Fernandez et. al., 2007). In addition, 
STAT5B is another important transcription factor involved in the JAK-STAT5 signalling 
pathway (Dalgic et. al., 2015). Interestingly, a recent report suggested that a STAT5-deificent 
mouse model increases thrombosis susceptibility through accelerating fibrin formation 
(Nordstrom et. al., 2010).  These studies showed that AP1 and Sp1 regulate several important 












1.6 Statement of Aims: 
Non-coding miRNAs are involved in regulating important physiological processes, and in the 
pathogenesis of various diseases. Recently, a role for miR-494 in the regulation of the 
coagulation pathway has been reported; where miR-494 was found to downregulate the 
expression of the anticoagulant factor, PS, through direct binding within the 3’UTR sequence 
of PROS1 mRNA transcript. Further studies also demonstrated that miR-494 was able to 
regulate the expression of multiple coagulation factors at the mRNA levels, including those 
without predicted miR-494 binding sites within their 3’UTR sequences. Therefore, it is 
hypothesised that miR-494 has an important role in the regulation of haemostasis and 
coagulation pathways by targeting multiple coagulation factor genes via both direct and 
indirect mechanisms.  
 
 
Hence, the aims of this study are to further characterise miR-494 function by: 
1. Determining the effects of miR-494 on regulating coagulation factors’ (PS, PLG, 
C4BPA and TF) protein levels. 
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2.1 Chemical Reagents 
2.1.1 Cell Culture 
Item Company Catalog No. 
0.25% Trysin-EDTA Gibco Life Technologies, USA 25200-056 
DMEM  Gibco Life Technologies, USA 21063-029 
Fetal Bovine serum 
Charcoal Stripped 
PA`A Laboratories GmbH, Germany  A11-519 
Metafectene®  Pro Biontex Laboratories GmbH, Germany T040-5.0 
Penicillin Streptomycin  Gibco Life Technologies, USA 15140-122 
RPMI-1640 Medium Gibco Life Technologies, USA 11835-030 
Sodium pyruvate (100mM) Gibco Life Technologies, USA 11360-070 
Non-essential amino acids Gibco Life Technologies, USA 11140-050 
HuH-7 cell line Given by Mark Watson (IIID, Murdoch) 
MCF-7 cell line Given by Jacky Bentel (Royal Perth Hospital)  
 
2.1.2 Total RNA extraction 
Item Company Catalog No. 
RNAlater®  Stabilization Solution AmbionTM Life Technologies, USA AM7021 
RNaseZap®  RNase  
Decontamination Solution 
AmbionTM Life Technologies, USA AM9780 
Ethanol Ajax Finechem Pty. Ltd, USA 5077-20L 
mirVanaTM PARISTM Kit AmbionTM Life Technologies, USA AM1556 
 Cell disruption buffer  
 2x denaturing solution 
 Acid-phenol:choloroform  
 miRNA Wash solution 1 
 Wash solution 2/3 
 Elution solution 
TURBO DNA-freeTM Kit InvitrogenTM Life Technologies, USA AM1907 
 10x TURBO DNase buffer 
 TURBO DNase 
 DNase Inactivation Reagent 
 
2.1.3 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Item Company Catalog No. 
SuperScriptTM III Reverse  
Transcriptase 
InvitrogenTM Life Technologies, USA 18080-044 
Random Hexamers (50µM) InvitrogenTM Life Technologies, USA N8080127 
RNaseOUTTM Recombinant RNase 
Inhibitor 
InvitrogenTM Life Technologies, USA 10777-019 
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0.1M DTT InvitrogenTM Life Technologies, USA 18080-044 
5x First Strand Buffer InvitrogenTM Life Technologies, USA 18080-044 
10mM dNTPs InvitrogenTM Life Technologies, USA 18427-013 
 
2.1.4 Real-time Polymerase Chain Reaction (qPCR) 
TaqMan®  assay from Applied BiosystemsTM Life Technologies, USA  
Item Catalog No. Assay ID 
TaqMan®  Universal Master Mix II, no UNG 4440040  
TaqMan®  Gene Expression Assay, PROS1 (human) 4331182 Hs00165590_m1 
TaqMan®  Gene Expression Assay, PLG (human) 4331182 Hs00264877_m1 
TaqMan®  Gene Expression Assay, C4BPA (human) 4331182 Hs00426339_m1 
TaqMan®  Gene Expression Assay, F3 (human) 4331182 Hs01076029_m1 
TaqMan®  Gene Expression Assay, JUN (human) 4331182 Hs01103582_s1 
TaqMan®  Gene Expression Assay, SP1 (human) 4331182 Hs00916521_m1 
TaqMan®  Gene Expression Assay, STAT5B (human) 4331182 Hs00273500_m1 
TaqMan®  Gene Expression Assay, 18S (human) 4331182 Hs99999901_s1 
TaqMan®  Gene Expression Assay, ACTB (human) 4331182 Hs99999903_m1 
TaqMan®  Gene Expression Assay, GAPDH (human) 4331182 Hs02758991_g1 
 
2.1.5 Western Blot 
Item Company Catalog No. 
β-mercaptoethanol Gibco Life Technologies, USA 21985-023 
Glycine Sigma-Aldrich Co., USA  G8898 
Methanol (AnalaR NORMAPUR) VMR International Pty Ltd., Australia 20847.307 
Precision Plus Protein TM 
Dual Strandard 
Bio-Rad Laboratories Inc., USA 161-0374 
Precision Plus Protein TM 
WesternC Standard  
Bio-Rad Laboratories Inc., USA 161-0376 
Sodium Chloride Amresco Inc., USA X190-1kg 
Sodium dodecyl sulfate Amresco Inc., USA 0227 
Sucrose AnalaR 10274 
Trizma®  Base Sigma-Aldrich Co., USA T6066 
Tween 20 British Drug Houses, London 663684B 
ClarityTM Western ECL substrate Bio-Rad Laboratories Inc., USA 170-5061 
0.1% Ponceau S with 5% acetic acid Sigma-Aldrich Co., USA P-7170 
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Hydrochloric acid Amresco®  LLC, USA A1367-2.5L 
Skim milk powder Fonterra Foodservices, Australia - 
 
2.1.6 Bacterial Culture and Plasmid Extractions 
Item Company Catalog No. 
Ampicillin sodium salt Sigma-Aldrich Co., USA A9518 
Yeast extract, bacteriological  Amresco®  LLC, USA J850-500G 
Tryptone (bacteriological grade) Amresco®  LLC, USA J859-500G 
Sodium chloride Amresco®  LLC, USA X190-1kg 
Riedel-de Haën®  Sodium hydroxide Sigma-Aldrich Co., USA 06203 
NucleoBond®  Xtra Midi Endotoxin- 
free plasmid DNA 




2.1.7 Luciferase Reporter Assay 
Item Company Catalog No. 
Firefly substrate (10x) Gene Stream Pty. Ltd, Australia - 
5x lysis Buffer Gene Stream Pty. Ltd, Australia - 
Firefly enhancer (10x) Gene Stream Pty. Ltd, Australia - 





2.2 Laboratory Equipment 
2.2.1 General 
Item Company Catalog No. 
Weigh Tray (72x72mm)  Sarstedt Australia Pty Ltd, Australia 71.9923.212 
Weigh Tray (128x128mm)  Sarstedt Australia Pty Ltd, Australia 71.9923.210 
2mL tube Axygen®  Corning Inc, USA MCT-200-C 
5mL tube Sarstedt Australia Pty Ltd, Australia 63.9921.522 
FalconTM 15mL tube Thermo Fisher Scientific, USA 05-527-90 
FalconTM 50mL tube Thermo Fisher Scientific, USA 14-432-22 
0.2mL thin wall PCR tubes Axygen®  Corning Inc, USA AXYPCR02LC 
Parafilm M®  Bemis Company, Inc., USA PM996 




2.2.2 Cell culture and Total RNA extraction 
Item Company Catalog No. 
FalconTM Tissue Culture Flask, 75cm2 Thermo Fisher Scientific, USA 353136 
Cellcoat®  Petri Dishes 100x20mm  Greiner Bio-One, Australia  664160 
Countess automated cell counter InvitrogenTM Life Technologies, USA - 
Allegra®  X15R Centrifuge Beckman Coulter Inc., USA - 
AllegraTM 25R Centrifuge Beckman Coulter Inc., USA - 
 
2.2.3 RT-PCR and qPCR 
Item Company 
Microfuge®  16 Centrifuge Beckman Coulter Inc., USA 
C100TM Thermal Cycler Bio-Rad Laboratories Inc., USA 
CFX96TM Real-Time PCR Detection  
System 
Bio-Rad Laboratories Inc., USA 
CFX384TM Real-Time PCR Detection 
System 
Bio-Rad Laboratories Inc., USA 
 
2.2.4 Western Blot 
Item Company Catalog No. 
Mini-protean®  TGXTM Gel 
4-15% 10 well comb 
Bio-Rad Laboratories Inc., USA 456-1083 
Mini-protean®  Tetra cell 
4 Gel system 
Bio-Rad Laboratories Inc., USA 165-8004 
Amersahm TM Protran TM   
0.45µm NC 
GE Healthcare Life Sciences, 
Germany 
10600016 
Medium Reciprocating Shaker Ratek Laboratory Equipment, Australia RM2 
Power PAC 3000 Bio-Rad Laboratories Inc., USA - 
Fusion-FX Vilber Lourmat, Germany - 
Transfer tank Bio-Rad Laboratories Inc., USA - 
 
2.2.5 Luciferase Reporter Assay 
Item Company Catalog No. 
24 well plate   
Micro-Assay 96 wells plate Greiner bio-one International GmbH, 
Germany 
655098 




Antibody Company Catalog No. 
Rabbit anti-human C4BPA antibody PierceTM Thermo Fisher Scientific, USA PA5-25861 
Rabbit anti-human TF antibody PierceTM Thermo Fisher Scientific, USA PA5-27278 
Rabbit anti-human PROS1 antibody Sigma-Aldrich Co., USA SAB2107166 
Rabbit anti-human TFPI antibody Sigma-Aldrich Co., USA SAB1408636 
Rabbit anti-human PLG antibody Santa Cruz Biotechnology Inc., USA SC-25546 
Mouse anti-human THBS1 antibody Santa Cruz Biotechnology Inc., USA SC-393504 
Rabbit anti-human ADAMTS13 
antibody 
Santa Cruz Biotechnology Inc., USA SC-25584 
Goat anti-human Actin antibody Santa Cruz Biotechnology Inc., USA SC-1616 
Goat anti-rabbit IgG-HRP  Santa Cruz Biotechnology Inc., USA SC-2004 
Donkey anti-goat IgG-HRP  Santa Cruz Biotechnology Inc., USA SC-2020 
Goat anti-mouse IgG-HRP  Santa Cruz Biotechnology Inc., USA SC-2005 
 
 
2.4 Computer Programmes 
Programme Company 
Microsoft Excel Microsoft®  Corporation, USA 
Bio-Rad CFX Manager Bio-Rad Laboratories Inc., USA 
BioProfil®  Bio1D Bio-Profil Polska, Poland 
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3.1 Computational analyses 
3.1.1 Identifying putative miR-494 binding sites in the 3’UTR sequences of transcription 
factor genes 
 
Online miRNA binding site prediction tools, MicroRNA.org (http://www.microrna.org/), RegRNA 1.0 
(http://regrna.mbc.nctu.edu.tw/index1.php) and, TargetScan 7.0 (http://www.targetscan.org/) were used to 
identify putative binding sites for hsa-miR-494 (MI0003134) in the 3’UTR sequences of JUN, 
SP1, STAT5B. The 3’UTR sequences of JUN, SP1 and STAT5B were obtained from Ensembl 
data base (Table 3.1). 
 
Table 3.1. Ensermbl genome ID and numbers of base pairs of the 3’UTR sequences of the target 
gene. 
3’UTR Sequences Ensembl Genome ID Sequence Length (bp) 
JUN ENST00000371222 1287 
SP1 ENST00000426431 5206 
STAT5B ENST00000293328 2570 
 
 
3.1.2 Identification of transcription factor binding sites in the promoter region of 
coagulation factor genes. 
 
PROSCAN 1.7 (http://www-bimas.cit.nih.gov/molbio/proscan/) and PROMO analysis 3.0.2 
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) were prediction tools 
for predicting transcription factor binding sites in a gene sequence. The 20,000 bases 
upstream of the transcription start site of PLG, C4BPA and F3 were obtained from the Ensembl 
data-base (Table 3.2.), and analysed by PROMO to identify putative binding sites for 
transcription factors with a 15% maximum matrix dissimilarity rate. 
 
 
Table 3.2. Ensermbl genome ID for the promoter regions of coagulation factor. 








3.2 Cell Culture 
3.2.1 Maintenance of HuH-7 and MCF-7 cell lines 
The human liver carcinoma cell line, HuH-7, was cultured in phenol red-free Dulbecco’s 
Modified Eagle Medium (DMEM) medium1, supplemented with 10% (v/v) fetal calf serum 
(FCS), 10mM sodium pyruvate (NaPyr/C3H3NaO3), 100 IU/mL penicillin, 100 IU/mL 
streptomycin and 10mM non-essential amino acids solution (NEAA). Human breast cancer 
cell line, MCF-7, was maintained in phenol red-free RPMI-1640 medium2, containing 10% (v/v) 
FCS, 10mM NaPyr, 100 IU/mL penicillin and 100 IU/mL streptomycin.   
 
Both HuH-7 and MCF-7 cells were grown at 37°C/5% CO2 and observed every 2-3 days using 
the Nikon Eclipse TS100 light microscope to monitor cell confluency. The culture medium was 
replaced every 2-3 days and cells were passaged when they were above 80% confluence. To 
passage the cells, medium was removed from the flask and washed with 4-5mL of Phosphate 
Buffered Saline (PBS)3 to remove any remaining culture medium, after which 2mL of 0.25% 
trysin-EDTA was added into the flask and incubated at 37°C/5% CO2 for approximately 2min 
until the cells have started to detach from the plastic culture surface. The trysin-EDTA was 
inactivated by adding an equal or greater volume of fresh culture medium. HuH-7 and MCF-7 
cells were passaged at 1:15 and 1:10 dilutions respectively at which the cells will reach 
confluency and be passaged once a week. 
 
3.2.2 miR-494 transfection in HuH-7 
To determine miR-494 effects on the mRNA and protein expression of target genes, HuH-7 
cells were transfected with 50nM negative control miRNA (miR-NC) or 50nM miR-494 
precursors. HuH-7 cells were trypsinised (section 3.2.1) and the concentration and viability of 
the cell suspension were determined using the Countess Automated Cell Counter 
(InvitrogenTM Life Technologies). A total of 1.5 x 106 or 2.0 x 106 cells were seeded in each 
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10cm Petri dish with 10mL of stock culture medium and incubated overnight at 37°C/5% CO2. 
The next day, the cells were transfected with 50nM miR-NC or miR-494 using Metafectene®  
Pro transfection reagent according to the manufacturer’s instructions. For transfections in a 
10cm Petri dish, 700µL of DMEM media alone (without antibiotics and other supplements) and 
10µL of 50µM pre-miR-NC or pre-miR-494 (Solution A) was added into 700µL of DMEM media 
and 42µL of Metafectene®  Pro (Solution B), pipetted once to mix and incubated for 15min at 
room temperature. The medium in the petri dishes was replaced with 8.6mL of fresh culture 
medium just before the addition of the transfection mix to ensure a total final volume of 10mL. 
The transfection mix was added to the cells dropwise and the HuH-7 cells in Petri dishes were 
incubated at 37°C/5 % CO2 and harvested at 48h or 72h post transfection before they were 
harvested by trysinisation (section 3.2.1) for total RNA extraction (section 3.3.1) or for the 
preparation of whole cell lysates for western blotting (section 3.5.1) 
 
To harvest the cells, all medium was removed from the petri dishes and washed with 4-5mL 
of PBS3, after which 2mL of trysin-EDTA was added and incubated at 37°C for 1-2min to 
dislodge the cells from the plastic culture surface. Countess automated cell counter and the 
EVETM cell counting slide were used again for counting cell numbers and determining cell 
viability. A total of 2.0 x 106 of cells were transferred into a clean tube for total RNA extraction 
(section 3.3.1) and the remaining cells were lysed with whole cell lysis buffer16 for use in 










3.3 Total RNA extraction 
3.3.1 Total RNA Extraction 
mirVanaTM PARISTM Kit from Ambion life technologies was used for total RNA extraction. The 
trypsinised transfected cells were centrifuged using the Beckman Coulter Allegra®  X-15R 
centrifuge at 359xg at room temperature for 5min. The culture supernatant was removed and 
1mL of RNAlater®  solution was added and the cell pellets were resuspended by pipetting up 
and down. The cell suspension was stored at 4°C for at least 24h up to a week before RNA 
extraction. An equal volume of PBS3 (1mL) added into the cell suspension in RNAlater®  
solution and centrifuged at 3157xg for 10min at room temperature and the RNAlater®   solution 
was removed. For RNA extraction, 500μL of ice-cold cell disruption buffer was added and the 
cell pellet resuspended by vortexing. An equal amount of 2x denaturing solution (500μL) 
warmed to 37°C was then added and incubated in ice for 10min. After the incubation, 1mL of 
acid-phenol:chloroform was added into the mixture, and vortexed vigorously to mix for 30s to 
obtain an emulsion. The mixture was then centrifuged using Beckman Coulter AllegraTM 25R 
centrifuge for 5min at 10,000xg at room temperature to separate the aqueous and organic 
phases. Checking that the interphase is compact after centrifugation, 800μL of the aqueous 
(top) phase were carefully removed and transferred into a fresh 2mL tube for RNA isolation. 
 
To isolate the total RNA, 1.25 volume of room temperature 100% ethanol (v/v) (1mL) was 
added into the lysate and mixed it using a pipette. Each sample was transferred into the 
collection tubes with a filter cartridge and centrifuged at 10,000xg for 1min at room 
temperature allowing the mixture to pass through the filter. After all the lysate/ethanol had 
passed through the filter, the filter was washed with 700μL of miRNA wash solution 1, followed 
by two washed with 500μL of wash solution 2/3, with centrifugation at 10,000xg between 
washes. After the third wash, the filter was centrifuged in the collection tube to remove any 
residual wash buffer and transferred into a fresh collection tube. To elute the total RNA, 100μL 
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of preheated elution buffer (95°C) was applied into the filter cartridge and centrifuged at 
10,000xg for 1min at room temperature. 
 
3.3.2 DNase Treatment 
Turbo DNA-freeTM kit was used for digesting the DNA to eliminate genomic DNA contamination 
from the eluted RNA according to the manufacturer’s protocol. Briefly, 10μL of 10x Turbo 
DNase buffer and 1μL of Turbo DNase were added into the extracted RNA, and incubated at 
37°C for 30min. To inactive the DNase activity, 10μL of the DNase inactivation reagent were 
added and incubated at room temperature for 5min with constant mixing. The mixture was 
centrifuged at 10,000xg for 1.5min at room temperature by using Beckman Coulter 
Microfuge®  16 centrifuge to pellet the DNase inactivation reagent. The clear aqueous top layer 
containing the total RNA was transferred into a clean tube, the concentration and quality of 
the extracted RNA were determined by using ND 1000 spectrophotometer, and the total RNA 
was aliquoted in multiple 20μL volumes into RNase-free tubes and stored at -80°C.  
 
 
3.4 Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) 
3.4.1 Reverse Transcription  
Total RNA was converted to cDNA using Superscript III reverse transcriptase (InvitrogenTM 
Life Technologies) before performing qPCR. For first strand synthesis, 1µL of 50µM random 
hexamers, 1µL of 10mM dNTP mix19, 1µg of total extracted RNA (section 3.3.5) and 6µL of 
distilled water were added into a fresh nuclease-free microcentrifuge tube. The mixture was 
heated to 65°C for 5min and incubated in ice for 2min. For cDNA conversion, a master mix 
containing 4µL of 5x first-strand buffer, 1µL of 0.1M DTT, 1µL of 40U/µL RNaseOUTTM 
recombinant RNase inhibitor and 1 µL of 200U/µL SuperScriptTM III Reverse Transcriptase 
was added into the mixture. The mixture was mixed and incubated at 25°C for 5 min, followed 
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by 55°C for 60min and the reaction was inactivated by heating at 70°C for 15min. The cDNA 
was used immediately for qPCR or stored at -20°C until required. 
 
3.4.2 Quantitative PCR (qPCR) 
Levels of PROS1, PLG, C4BPA, TF, JUN, SP1 and STAT5B mRNA were determined by using 
TaqMan Gene Expression Assay and normalised to mRNA levels of housekeeping genes 
18S, β-Actin (ACTB) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which were 
the endogenous controls in this experiment. The master mixes were prepared with 0.5µL of 
20x TaqMan Gene Expression Assays and 5µL of 2x master mix reagents per well, and vortex 
the master mix. The master mixes (5.5µL) were loaded into each well of a 96-well PCR 
reaction plate. The cDNA was diluted 1:7 with RNase-free water and 4.5µL of the diluted cDNA 
were loaded into the 96-wells reaction plate in triplicates. The plate was placed in the BioRad 
Real-Time PCR Detection System and cycled under the following conditions: 95°C for 10min, 
followed by 40 cycles of 95°C for 15s and 60°C for 1min. The relative fold changes to mRNA 
levels were calculated by the 2-ΔΔCT method. 
 
 
3.5 Western Blotting 
3.5.1 Harvesting cells for western blot 
To prepare cell lysates for western blotting, total cell numbers in the trypsinised cell 
suspensions were determined on the countess automated cell counter and the EVETM cell 
counting slide. The cells were pelleted by centrifugation at 359xg at room temperature for 
5min. All the supernatants were removed and the cells were lysed with whole cell lysis buffer16 
(250mL lysis buffer for every 2.0 x 106 cells). The lysates were drawn repeatedly through a 
23G needle into a 1mL syringe unit until the viscous lysates reached a water-like consistency 
due the shearing of genomic DNA, and the lysates were stored at -20°C. 
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3.5.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Denaturing SDS-PAGE was performed to separate the proteins according to their molecular 
weight. To prepare whole cell lysates for SDS-PAGE, 18µL of each sample was transferred 
into 0.2mL PCR tubes with 2µL of western 10x loading dye15. All the samples were heated at 
95°C for 8min to denature the proteins, after which the samples were loaded into 4-15% TGX 
precast gradient gel (Bio-Rad Laboratories Inc.). The gel was electrophoresed at constant 
voltage of 200V for 30-35min or until the loading dye reached to the bottom of the gel. 
 
3.5.3 Western Transfer 
After gel electrophoresis, the gel was removed from the casting plates and placed in cold 
western transfer buffer12 to be assembled into the transfer cassette. The transfer cassettes 
were prepared in the following order; from the black side: a sponge, three pieces of filter paper, 
the gel, a piece of prewetted 0.45µm nitrocellulose or 0.45µm PVDF transfer membrane, three 
pieces of filter paper and a sponge. The 0.45µm nitrocellulose membrane wetted in the cold 
transfer buffer but the PVDF membrane can only be wetted in methanol. All the transfer 
membranes, filter paper and sponge were wetted before preparing the transfer cassettes and 
air bubbles between each layer were ejected. The transfer cassettes were inserted into the 
transfer tank with cold transfer buffer12 and were transferred at constant voltage 30V for 
overnight at 4°C. 
 
3.5.4 Immunoblotting 
The 0.45µm nitrocellulose or PVDF transfer membranes were removed from the transfer 
cassettes after overnight transfer. A reversible protein stain, Ponceau Red, was used to stain 
the membrane to check the overnight transfer was successful and complete. Deionised water 
was used to wash off excess ponceau red before immunoblotting. The membranes were 
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incubated in 3% (w/v) skim milk/TBST blotto blocking solution14 for 90min on a rotary shaker 
and then incubated with primary antibody diluted in 3% (w/v) skim milk/TBST blotto blocking 
solution14 for 90min. Primary antibody solution was removed and the membranes were 
washed with tris buffered saline with Tween 20 (TBST)13 for 3 x 5min. After the wash, the 
membranes were incubated in secondary antibody diluted in 3% (w/v) skim milk/TBST blotto 
blocking solution14 for another 90min, and washed 3 x 5min with TBST. The dilutions used for 
HRP-conjugated secondary antibodies are listed in Table. 3.3.  
Table 3.3. Dilution of HRP-conjugated secondary antibodies used for immunoblotting. 
Secondary antibody Dilution  
Goat anti-rabbit IgG-HRP  1:2000 
Donkey anti-goat IgG-HRP  1:2000 
Goat anti-mouse IgG-HRP  1:2000 
 
 
ClarityTM western enhanced chemiluminescence (ECL) substrate ((Bio-Rad Laboratories In.) 
was used for detecting immunoreactivity. Excess TBST on the membranes was removed by 
draining the liquid off onto a clean paper towel, after which the ECL substrate was added 
dropwise on to the membranes, ensuring that the entire membrane was covered. The 
membranes were incubated with ECL for 5min at room temperature, the excess liquid drained 
off onto a clean paper towel and the immunoreactivity detected by exposing the membranes 
in the Fusion-FX imager between 10sec up to 10min. The optical density of the protein bands 








3.6 Plasmid DNA Extraction and Purification 
DH5E. coli glycerol stocks containing pMIR-REPORT luciferase construct (see Appendix II) 
or pRL-SV40 Renilla luciferase vectors (see Appendix II) were inoculated into 5mL of lysogeny 
broth (LB) medium14 with ampicillin (1g/mL) overnight at 37°C with sharking and allowed to 
grow overnight. The next day, the overnight cultures were transferred into 100mL of fresh LB 
medium supplemented with 100g/mL ampicillin and incubated with sharking overnight at 
37°C, and harvested for plasmid extraction the next day. 
 
Plasmid constructs required for transient transfection (section 3.7) were extracted from 100mL 
of overnight DH5α E.coli culture using the NucleoBond®  Xtra Midi Endotoxin Free kit 
(Macherey-Nagel GmbH & Co.) according to the supplied protocol. To harvest the bacterial 
cells, the overnight bacterial culture was centrifuged at 4064xg and 4°C for 20min. The 
supernatant was poured off and the cell pellet was resuspended with 8mL of resuspension 
buffer containing RNase A by vortexing. The cells were then lysed with 8mL of lysis buffer, 
mixed by gentle inversion 5 times and incubated at room temperature for 5min. During this 
time, 15mL of equilibration buffer was applied on the column filter to equilibrate the 
NucleoBond®  Xtra column by gravity flow. Following incubation, the lysis buffer was 
neutralised with 8mL of neutralisation buffer and mixed completely by inversion. The 
neutralised bacterial cell lysate was slowly loaded into the column filter and allowed to pass 
through the filter by gravity flow. The filter was washed with 5mL of filter wash buffer and the 
filter was discard after all the solution follow through the filter. The NucleoBond®  Xtra column 
was then washed with 35mL of ENDO-EF wash buffer followed by 15mL of WASH-EF wash 
buffer. To elute the plasmid DNA from the column, 5mL of elution buffer was added into the 
column and the flowthrough elute containing the plasmid DNA collected in a clean 15mL tube. 
To precipitate the plasmid DNA, 3.5mL of isopropanol was added to the eluted DNA mixed 
well by inversion, and centrifuged at 4064g for 60min at 4°C. After centrifugation, the 
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supernatant was removed using a pasteur pipette, with special care taken to not disturb the 
plasmid pellet. The plasmid DNA pellet was washed with 2mL of 70% ethanol and centrifuged 
again at 4064g for 20min at room temperature (22°C). The supernatant was removed using a 
pasteur pipette, again taking care not to disturb the plasmid pellet and the pellet was air dried 
at room temperature approximately 30 - 60min, to evaporate off the mixture. The dried plasmid 
DNA pellet was dissolved in 200µL of endotoxin free water (H2O-EF). The concentration and 
quality of the extracted plasmid were determined by using ND 1000 spectrophotometer. The 
extracted plasmid DNA was aliquoted into 10µL aliquots into nuclease-free tubes and stored 
at -80°C.  
 
 
3.7 Transfection of luciferase reporter vectors and pre-miRNA precursors 
HuH-7 cells in T75 flasks were trypsinised (section 3.1.1) and seeded into 24-well cell culture 
plates at a density of 2.5 x 105 cells per well. The seeded plate was incubated at 37°C/5% 
CO2 overnight to allow the cells to adhere before transfection. In each well, HuH-7 cells were 
co-transfected with 50nM of pre-miR-NC or pre-miR-494, 100ng of pRL-SV40 Renilla 
luciferase vector and 400ng of the pMIR-REPORT Firefly luciferase vector containing the full 
PROS1, JUN, SP1 or STAT5B-3’UTR insert. To prepare the transfection reaction mix, 50µL 
of the DMEM medium alone (without antibiotics or additives) with luciferase vectors and pre-
miRNAs were added 50µL of the DMEM medium alone with Metafectene®  Pro, and incubated 
at room temperature for 15min. The transfection mixture was added dropwise into the 24-well 
cell culture plate and incubated at 37°C for 6h. After this time, the transfected cells were 
trysinised (section 3.2.1) and reseeded into a white 96-well cell culture plate, and incubated 





3.8 Dual Luciferase Reporter Assay 
After 24h post-transfection, the cells were lysed with 20µL of Firefly Lysis buffer per well and 
incubated at room temperature for 30min. To assay for luciferase activities, RapidReporter®  
Firefly glow assay kit and RapidReporter®  flash and glow assay kit from GeneStream 
Laboratory were used. For the detection of Firefly luciferase activity, 60µL of Firefly glow assay 
buffer containing the luciferin substrate diluted in Firefly luciferase buffer was added into each 
well. Renilla luciferase activity was detected with 60µL of Flash and Glow assay buffer 
containing coelantrazine substrate. The plate was incubated at room temperature for 10 to 
30min to allow the light signals to reach a steady glow phase before being measured on the 
VictorTM light luminescence counter. The relative luciferase activity was determined by the 
ratio of Firefly and Renilla counts and the miR-494 effects on these 3’UTR constructs (PROS1, 
JUN, SP1 and STAT5B) were determined by normalising the relative luciferase activity of miR-
494 transfected samples to the relative luciferase activity of miR-NC transfected samples.  
 
3.9 Statistical analysis 
Two-tailed Student’s t-test with unequal variance was performed for the statistical analyses in 
luciferase reporter assays, RT-qPCR and western blot. A value of p<0.05 was set as 

















4.1 Optimising Immunoblotting primary antibodies 
To analyse protein expression, both qualitative and quantitative, the primary antibodies 
required optimisation under western blotting conditions. Anti-human C4b binding protein α 
(C4BPA), plasminogen (PLG), Protein S (PS) and tissue factor (TF) antibodies were optimised 
for immunoblotting before quantitating the protein levels in HuH-7 following miR-494 
transfection. The best primary antibody dilutions to use and expected sizes of C4BPA, PLG, 
PS and TF in western blots were listed in Table 4.1 and Table 4.2 respectively. Rabbit anti-
human C4BPA, PLG and PS antibodies were blotted on a 0.45 µM nitrocellulose membrane 
with 3% (w/v) skim milk/TBST blotto blocking solution14. However, rabbit anti-human TF 
antibody did not show a clear band on the nitrocellulose membrane. Therefore, TF antibody 
was blotted on a 0.45 µM PVDF membrane with 5% (w/v) skim milk/TBST blotto blocking 
solution18 because a high background was observed with 3% (w/v) skim milk/TBST blotto 
blocking solution14. Unfortunately, rabbit anti-human tissue factor pathway inhibitor (TFPI) and 
ADAMTS13, and mouse anti-human thrombospondin 1 (THBS1) could not be optimised 
because non-reactive antibody or multiple non-specific bands were found in the optimisation 
blot (Figure 4.1 E-G). No band was found at the expected size of THBS1 and TFPI primary 
antibodies in the optimisation blots, and multiple non-specific bands were found in the 
ADAMTS13 primary antibody optimisation blot. The use of these primary antibodies required 
further optimisation. Due to time limitations, the primary antibodies of THBS1, TFPI and 
ADAMTS13 could not be optimised and the protein levels of these proteins were not 
determined in this study. 




Best dilution in 
optimisation blot 
Sigma-Aldrich Rabbit anti-human PS antibody 1:1000 1:1000 
Santa Cruz Rabbit anti-human PLG antibody 1:200 1:500 
PierceTM Rabbit anti-human C4BPA antibody 1:1000 1:200 
PierceTM Rabbit anti-human TF antibody 1:1000 1:2000 
Santa Cruz Rabbit anti-human ADAMTS13 antibody 1:200 - 
Santa Cruz Mouse anti-human THBS1 antibody 1:100 - 





Table 4.2 The expected and actual size of proteins 
Primary antibody Expected size 
size showed in 
optimisation blot 
Sigma-Aldrich Rabbit anti-human PS antibody 75 kDa 60–75 kDa 
Santa Cruz Rabbit anti-human PLG antibody 90 kDa 90 kDa 
PierceTM Rabbit anti-human C4BPA antibody 70 kDa ~ 110 kDa 
PierceTM Rabbit anti-human TF antibody 47 kDa ~65kDa 
Santa Cruz Rabbit anti-human ADAMTS13 antibody 176 kDa - 
Santa Cruz Mouse anti-human THBS1 antibody 165-198 kDa - 





















B   Santa Cruz Rabbit anti-human PLG antibody 
C   PierceTM Rabbit anti-human C4BPA antibody 
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D   PierceTM Rabbit anti-human TF antibody 












Figure 4.1 Primary antibodies optimised for immunoblot. Antibodies tested including rabbit anti-human 
PS antibody (A), rabbit anti-human PLG antibody (B), rabbit anti-human C4BPA antibody (C), rabbit 
anti-human TF antibody (D), rabbit anti-human ADAMTS13 antibody (E), mouse anti-human THBS1 
antibody (F) and rabbit anti-human TFPI antibody (G). Optimum immunoblotting conditions for the PS, 
PLG, C4BPA and TF primary antibodies were determined. 
F    Santa Cruz Rabbit anti-human THBS1 antibody 
G   Sigma-Aldrich Rabbit anti-human TFPI antibody  
53 
 
4.2 Effects of miR-494 on different coagulation factors in HuH-7 cells 
4.2.1 mRNA expression profile of PLG, C4BPA and TF in miR-494 transfected HuH-7 
cells 
 
To determine mRNA levels of PLG, C4BPA and F3, TaqMan®  Gene Expression Assay was 
used in three independent transfections. PROS1 mRNA was used a positive control. The 
mRNA levels of these coagulation factors were determined with 5.0nM miR-494 48h and 72h 
post-transfection. The mRNA levels of PROS1 and PLG were significantly decreased at ~55% 
and ~38%, respectively (p < 0.05). The mRNA expression of C4BPA showed an increasing 
trend, by ~35%, but not statistically significant (p = 0.06). F3 showed no significant changes 
in mRNA levels with miR-494 48h post-transfection. However, with 72h miR-494 post-
transfection, the F3 mRNA level was significantly increased by ~123% and the mRNA level of 
PLG was again significantly decreased by ~35% (p < 0.05). Taken together, RT-qPCR results 
demonstrated that exogenous miR-494 downregulated PROS1 and PLG mRNA levels, and 
upregulated C4BPA mRNA level (Figure 4.2). However, there was no significant changes in 








Figure 4.2. Effect of miR-494 in mRNA levels of coagulation factors in HuH-7 cells at 48h (A) and 72h 
(B) post-transfection. HuH-7 cells were transfected with 50nM negative control miRNA and miR-494, 
the transfected cells were harvested at 48h and 72h post-transfection. The mRNA levels were 
determined by RT-qPCR and normalised to three housekeeping genes (18S, ACTB and GAPDH), with 
the fold changes to mRNA levels calculated with 2-ΔΔCt. Results were from three independent 


































































4.2.2 Protein levels of PS, PLG, TF and C4BPA in miR-494 transfected HuH-7 cells 
 
The protein expression of PS, PLG, TF and C4BPA from three independent miR-494 
transfections were determined by western blot.  The protein levels were normalised with actin 
and student’s t-test was used in statistical analysis. The protein levels of PS and PLG were 
significantly decreased, by ~61% and ~69% respectively (p < 0.05), with 72h miR-494 post-
transfection. At 48h post-transfection, the PS protein level was significantly decreased by 
~50% (p < 0.05).  However, there was no significant changes in the protein levels of C4BPA 
and TF at both 48h and 72h post-transfection. The protein expression of C4BPA was 
increased, by ~34% and ~60% respectively, at both 48h and 72h post-transfection. The TF 
protein level was decreased by ~56% at 72h post-transfection but no changes at 48h post-
transfection. Therefore, exogenous miR-494 induced downregulation of PS, PLG and TF 







                    
 















































































Figure 4.3 Effect of miR-494 in protein expression of Protein S (A), plasminogen (B), C4b binding 
protein (C) and tissue factor (D) at 48h and 72h post-transfection. The relative protein levels were 
determined by densitometry scanning of the protein bands and normalised to β-actin. Graphed results 
were from the combined analysis of three independent transfections (* p < 0.05, ** p < 0.01). The PS 
and PLG protein levels were significantly downregulated with miR-494 transfection (A and B). 
Unfortunately, there was no significant changes in the protein expression of C4BPA and TF with the 





















































4.3.3 mRNA levels of JUN, SP1 and STAT5B in miR-494 transfected HuH-7 cells 
 
To determine the mRNA expression of the three transcription factors, HuH-7 cells were 
transfected with miR-494 for 48h and 72h and total RNA extracted for RT-qPCR. TaqMan®  
Gene Expression Assay was used and three independent transfections were performed to 
determine the expression of specific mRNA. The mRNA levels of SP1 and STAT5B was 
significantly decreased, by ~38% and ~52% respectively (p < 0.05), at 48h miR-494 post-
transfection (Figure 4.4). These results suggested that potential miR-494 binding sites may 
be present in the SP1 and STAT5B 3’UTRs. Unexpectedly, there was no significant changes 
in the JUN mRNA levels even through a predicted miR-494 binding site was found in the 
3’UTR sequence of JUN. At 72h miR-494 post-transfection, the mRNA levels of SP1 and 
STAT5B were decreased and the JUN mRNA level was significantly upregulated. Taken 
together, RT-qPCR results also showed that exogenous miR-494 downregulated SP1 and 














Figure 4.4. Effects of miR-494 in mRNA expression of transfection in HuH-7 cells at 48h (A) and 72h 
(B) post-transfection. HuH-7 cells were transfected with 50nM negative control miRNA and miR-494, 
the transfected cells were harvested at 48h and 72h post-transfection. The mRNA levels were 
determined by RT-qPCR and normalised to three housekeeping genes (18S, ACTB and GAPDH), with 
the fold changes to mRNA levels calculated with 2-ΔΔCt. Results were from three independent 




































































4.4 Computational analyses 
4.4.1 Computational analyses of the JUN, SP1 and STAT5B 3’UTR sequences 
Putative miR-494 binding sites were identified in the 3’UTR sequences of JUN, SP1 and 
STAT5B. Using the bioinformatic algorithms (miRanda, TargetScan and RegRNA), a more 
negative score of predicted miR-494 binding site indicates a stronger binding interaction with 
miR-494. According to the scores of predicted miR-494 binding sites from RegRNA, the miR-
494 binding site in STAT5B-3’UTR was stronger, when compared to the 3’UTR sequences of 
JUN and SP1, and binding site in the SP1-3’UTR was the weakest. A putative miR-494 binding 
site in the 3’UTR sequence of JUN were located near the end of the sequence (973-995). In 
contrast, the putative miR-494 binding site in the 3’UTR sequence of SP1 (1337-1375) and 





Table 4.3.  Putative miR-494 binding sites in the 3’UTR sequence of JUN, SP1 and STAT5B 
3’UTR 
sequence 
Putative miR-494 binding site miRanda TargetScan RegRNA 
JUN  
           3’ cuccaaAGGGCAC-AUACAAAGu 5’ JUN 
          |||  ||||||| 
973:5’aggataTCTTGTGCGATGTTTTCa 3’miR-494 
-0.1095 - -12.7 
SP1 
     3’ cucCAAAGGGCACAUACAAAGu 5’ SP1 
           | |||:: || ||||||: 
1337:5’ agtGGTTCTTATG-ATGTTTTc 3’miR-494 
- - -9.1 
STAT5B 
      3’  cuccaaAGGGCACAUACAAAGu 5’ STAT5B 
           ||::|||  ||||||:     
45:5’aatcacTCTTGTGGATGTTTTa 3’ miR-494 








4.4.2 Computational analyses of PLG, F3 and C4BPA promoter regions 
Two online transcription factor binding tools were used to identify the interaction between the 
three transcription factors (AP1, Sp1 and STAT5B) and the promoter region of PLG, F3 and 
C4BPA genes. The online transcription factor binding tools, PROMO 3.0.2 and PROSCAN 
1.7, showed that one or more AP1, Sp1 or STAT5B binding sites were found in the promoter 
region (up to 20kb upstream of transcription start site) of PLG, TF and C4BPA (Table 4.4.). 
The PROMO 3.0.2 results suggested that AP1 appeared to be targeting most of the 
coagulation factor, with 10, 18 and 19 predicted AP1 binding sites found in the promoter 
regions of PLG, F3 and C4BPA, respectively. The promoter region of F3 and PLG (from 
PROSCAN 1.7 results) contained a single Sp1 binding site. No Sp1 site was found in the 
C4BPA promoter; and no STAT5B binding site was found in the promoter region of the 
coagulation factors investigated.  
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Sequence dissimilarity Sequence dissimilarity Sequence dissimilarity Sequence dissimilarity 
        
C4BPA 2219TGACTTCTA2227 13.50% 3371TCAGAGTCA3379 5.50% -- --  
 3656TGACTCATC3664 0.00% 4300TGACTTTTC4308 13.57% -- --  
 6410TGACTGCTA6418 13.84% 6695AAGAAGTCA6703 13.42% -- --  
 7645GATAAGTCA7633 8.51% 7737TGGCAGTCA7745 13.90% -- --  
 8645AACAAGTCA8653 14.68% 8917CAAGAGTCA8925 5.32% -- --  
        
F3 544 ATAGAGTCA522 5.46% 1236 TGACTACTG 1244 13.67% 9795AGGGCGGGAA9804 2.52%   
 1617GAAGAGTCA1625 5.06% 1790CAGAAGTCA1798 13.33% -- --  
 2536AGGAAGTCA2544 13.47% 3077TGACTTCAA3085 13.56% -- --  
 3843AAAAAGTCA3851 13.92% 4976TGACTTTGG4984 13.84% -- --  
 5549TGACTAAAC5457 8.91% 6624TGACTGATT6632 9.20% -- --  
 7187TGACTGTAA7195 14.40% 7576TGACTTTGC7584 13.57% -- --  
 7663CCAAAGTCA7671 13.84% 8495TGACTTTTC8503 13.57% -- --  
 8724TGACTTCTG8732 13.33% 8930CTGCAGTCA8938 13.72% -- --  
 9217TGACTGACC9225 8.91% 9755TGACCTGT9763 5.41% -- --  
         
PLG 300TGACTGAAC308 8.91% 836TGACTCTCA844 5.55% 3061GGCGG3065 59.31 --  
973CGATAGTCA981 14.23% 1381GTTGAGTCA1389 0.05% -- --  
1425ATGGAGTCA1433 4.96% 1505TGACTTACC1513 8.57% -- --  
2503TCTCAGTCA2511 9.29% 3086ATTCAGTCA3094 9.26% -- --  
3090AGTCAGTCA3098 9.26% 5157TGACTGTCT5165 14.32% -- --  
4268GAGAAGTCA4276 13.07% 4950TGACTTATC4958 8.51% -- --  
6221TGACTTGGC6229 14.33% 6890TGACTTGTA6898 14.77 -- --  
7554GAAAAGTCA7562 13.57% 7855TGAGAGTCA7863 5.55% -- --  
8503CCCAAGTCA8511 14.59% 8801GGTGAGTCA8809 0.05% -- --  
9956TGACTATCT9964 14.32%       
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4.4 Functional miR-494 binding sites in the SP1 and STAT5B 3’UTRs 
Section 4.3.3 showed reduced mRNA levels of SP1 and STAT5B following miR-494 
transfection. To determine the direct interaction between the miR-494 and the 3’UTR 
sequences of affected transcription factors, luciferase reporter constructs containing PROS1, 
JUN, SP1 and STAT5B-3’UTR were produced. Functional miR-494 binding sites were 
identified in the previous study by Tay et. al. (2013), therefore, PROS1-3’UTR luciferase 
reporter construct was used as a positive control for this study. Dual luciferase reporter assay 
showed that the luciferase activity of SP1 and STAT5B-3’UTR was significantly decreased, by 
~12% and ~23% respectively (p < 0.05), with increasing miR-494 concentration. No significant 
changes was observed in the luciferase activity of the JUN-3’UTR reporter construct. 
Therefore, dual luciferase reporter assay results suggested that a functional miR-494 binding 
site was present in the 3’UTR sequence of SP1 and STAT5B. The dual luciferase reporter 
assay results were concordant with the RT-qPCR results analysing the mRNA levels of JUN, 
SP1 and STAT5B following miR-494 transfection. 
 
Figure 4.5 Direct interaction between the miR-494 and the transcription factors 3’UTRs. HuH-7 cells 
were cotransfected with pmiR-PROS1, JUN, SP1 and STAT5B-3’UTRs luciferase reporter and 50nM 
negative control miRNA or 50nM miR-494. The luciferase activity were analysed at 24h post-



















































The roles of miRNAs have been identified in the regulation of key cellular processes and 
pathophysiology of various cancers. Recently, a number of miRNAs has been ascribed roles 
in regulating the coagulation cascade and haemostasis. Several miRNAs regulate the 
expression of microparticles in platelet aggregation or the development of megakaryocytes 
through targeting different transcription factors (Garzon et. al., 2006; Landry et. al., 2009). 
Moreover, multiple miRNAs regulate the expression of two major procoagulants, fibrinogen 
and TF (Fort et. al., 2010; Li et. al., 2014b). However, the role of miRNAs in coagulation and 
haemostasis is still poorly characterised. A recent study by Tay et al. (2013) reported that miR-
494 directly downregulates the PS mRNA levels by binding to the PROS1 mRNA-3’UTR. 
Further investigations on the miR-494 functions in coagulation demonstrated that 
overexpression of miR-494 in HuH-7 cells resulted in significant changes in the mRNA levels 
of multiple coagulation factors, including those lacking miR-494 binding sites in their 3’UTR 
sequences (Dr. Jasmine Tay, personal communication). These results strongly suggested that 
miR-494 plays an important role in coagulation and haemostasis, and may also be important 
in the development of thrombotic diseases. The present study demonstrated that miR-494 can 
directly or indirectly regulate multiple coagulation factors to promote thrombosis. 
 
Seven untested primary antibodies required optimisation for immunoblotting experiments. 
Four of the seven primary antibodies (PS, PLG, C4BPA and TF) were optimised with the 
optimum dilutions, determined to be 1:1000, 1:500, 1:200 and 1:1000 respectively. The 
optimisation blot of PS and PLG primary antibodies showed that these two protein sizes were 
came out as expected. However, the observed protein size of C4BPA and TF was larger than 
the expected size possibly due to difference in SDS-PAGE resolution and/or post-translational 




SDS-PAGE migration is one of the explanation that observed C4BPA and TF protein sizes 
are not the same as their formula molecular weights. Rath et al. (2009) reported that the 
observed protein size of membrane proteins does not always correlate with calculated 
molecular weights. They suggested that altered SDS binding is mainly caused by abnormal 
protein-detergent contacts, such as incomplete denaturation. However, in some cases, SDS-
PAGE migration can be caused by protein-protein contacts, suggesting that the protein folding 
may be involved in SDS-PAGE migration (Rath et. al., 2009).   
 
Post-translational modification (PTM), such as phosphorylation, sumoylation and 
ubiquitination, is an enzymatic modification of protein to increase functional diversity of a 
protein. Protein phosphorylation is one example of PTM which allows activation or inhibition 
of proteins by cleaving regulatory subunits or protein degradation. Several studies on 
phosphorylation of TF demonstrated that the cytoplasmic domain of TF, containing two 
phosphorylation sites, and is rapidly phosphorylated by the activation of protein C kinase α 
(Zioncheck et. al., 1992; Dorfleutner and Ruf, 2003). Moreover, online prediction tools, 
NetPhosK 1.0 (http://www.cbs.dtu.dk/services/NetPhosK/), SUMOplotTM Analysis Program 
(http://www.abgent.com/sumoplot) and UbPred (http://www.ubpred.org/) were used for identifying protein 
phosphorylation, sumoylation, and ubiquitination sites in the peptide sequences. The results 
showed that multiple protein C kinase phosphorylation sites were identified in the TF and 
C4BPA proteins. Three predicted sumoylation sites and three predicted ubiquitination sites 
were found in the TF protein. In contrast, five predicted ubiquitination sites and eight 
sumoylation sites were found in the C4BPA protein. These suggested that PTM could explain 
the larger TF and C4BPA protein size shown in the optimisation blot. Moreover, PTM of 
coagulation factors is not only restricted in the TF and C4BPA proteins. Vitamin K-dependent 
plasma proteins, including Protein C (PC) and PS, are also modified during or after protein 
biosynthesis. The PTM of PC and PS is often through γ-carboxylation, undertaken by a vitamin 
K-dependent carboxylase to convert glutamate to carboxyglutamate; and N-linked 
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glycosylation (Walsh and Jefferis, 2006). Both γ-carboxylation and N-linked glycosylation are 
processed in the endoplasmic reticulum. 
 
The TFPI, ADAMTS13 and THBS1 primary antibodies optimisation could not be completed in 
this study due to time constraints. The TFPI antibody optimisation blot showed that the protein 
of interest was presented in the MCF-7 cells but not in the HuH-7 cells. Under normal 
physiological condition, TFPI is primarily expressed in megakaryocytes and microvascular 
endothelial cells but not highly synthesised by hepatocytes (Osterud et. al., 1995). Therefore, 
the HuH-7 cell line was not the best cell line for optimising the TFPI primary antibody. TFPI, 
ADATMS13 and THBS1 primary antibodies were blotted with two different blocking conditions, 
3% and 5% (w/v) skim milk/TBST blotto blocking solution. Moreover, the SDS-PAGE gels for 
optimising the ADATMS13 and THBS1 primary antibodies were electrophoresed for 2.5 hours 
at a low constant amps (25mA). Therefore, the presence of multiple non-specific bands maybe 
caused by low quality primary or secondary antibodies. Further optimisation of the ADATMS13 
and THBS1 primary antibodies is required for analysing their protein levels in miR-494 
transfected HuH-7 cells. 
 
The mRNA and protein levels of the four coagulation factors were determined in HuH-7 cells 
with the miR-494 transfection. According to the pervious results obtained in our laboratory, the 
mRNA expression of two anticoagulants, PROS1 and PLG, was significantly decreased with 
increasing concentration of miR-494. Conversely, the mRNA level of multiple procoagulants, 
including C4BPA and F3, was significantly increased at 48h post-transfection (Tay et al. 
unpublished results). In this study, the results showed that only PROS1 and PLG mRNA levels 
were significantly decreased at 48h post-transfection, which supported the previous results 
performed in the laboratory. There is a considerable trend towards significant change in 
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upregulation of C4BPA mRNA level at 48h miR-494 post-transfection. No changes in the F3 
mRNA levels were detected in miR-494 transfected HuH-7 cells. 
 
In this study, the protein levels of PS, PLG, C4BPA and TF was determined at 48h and 72h 
miR-494 post-transfection in HuH-7 cells. Western blot results showed that exogenous miR-
494 significantly downregulates the protein expression of PS and PLG, and upregulates the 
C4BPA protein level, which is concordant with the RT-qPCR results analysing their mRNA 
levels. Moreover, the RT-qPCR results showed that the F3 mRNA levels were upregulated at 
72h miR-494 post-transfection and no change was identified at 48h post-transfection. 
However, western blot results showed TF protein expression was downregulated at 72h miR-
494 72h post-transfection, which did not correlate with its mRNA level. One explanation is that 
the western blot detected intracellular protein, whereas TF is naturally transported to the cell 
surface and secreted (Drake et. al., 1989). This may be a possible explanation of negative 
correlation between TF mRNA and protein levels. Further investigations on the miR-494 
effects of TF protein expression in the media are required. Taken together, the prothrombotic 
effect of miR-494 can be achieved through repressed PS and PLG expression, and enhanced 
C4BPA expression. 
 
The results showed that functional miR-494 binding sites are present in the 3’UTR sequences 
of SP1 and STAT5B, and the mRNA levels of SP1 and STAT5B were significantly 
downregulated with miR-494 transfection. These suggested that miR-494 downregulates SP1 
and STAT5B mRNA levels by binding to the 3’UTR sequence of SP1 and STAT5B mRNA 
transcripts. Moreover, the expression of PLG, which lacks a miR-494 binding sites in its 3’UTR 
sequence, was significantly downregulated with miR-494 transfection. Computational analysis 
showed that a predicted Sp1 binding site was found in the promoter region of human PLG 
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gene, which suggested that Sp1 may be a transcriptional activator or repressor of PLG gene. 
Taken together, miR-494 may downregulate the PLG expression indirectly by targeting SP1.  
 
The results suggested that miR-494 directly downregulates SP1 mRNA expression by binding 
to the SP1 mRNA-3’UTR sequence. Sp1 is an important transcription factor in other cell 
signalling pathways (Figure 5.1), therefore, miR-494 may indirectly regulate multiple gene 
expression, such as p53 and p21, to inhibit tumourigenesis or regulate the cell cycle through 
Sp1 downregulation (Kavurma and Khachigian, 2004; Knappskog et. al., 2011). In addition, 
miR-494 may regulate PLG expression through downregulating Sp1 expression because a 








Sp1 regulates the expression of important transcription factors, such as p53, to inhibit 
tumourigenesis. Sp1 enhances the gene expression of E3 ubiquitin-protein ligase (MDM2), a 
key regulator of p53, via binding to the MDM2 promoter region (Knappskog et. al., 2011; 
Knappskog and Lonning, 2011). Increased expression of MDM2 results in the repression of 
p53 expression and the development of cancer. These suggested that miR-494 may enhance 
p53 expression via Sp1-mediated transcriptional regulation of MDM2, leading to the inhibition 
of tumourigenesis.  
 
Sp1 can acts as both transcriptional activators and repressors to activate or repress the gene 
expression of p21, a cyclin-dependent kinase (CDK) inhibitor, through two different 
mechanism. Biggs et al. (1996) reported that Sp1 binding sites were identified in two major 
regions of the p21 promoter. These Sp1 binding sites were essential for activating the p21 
transcription. Moreover, five Sp1-binding elements were identified in the promoter region of 
p21 (Kavurma and Khachigian, 2004). Further studies on these Sp1-binding elements showed 
that mutations of two specific elements result in the activation of p21 promoter, interestingly, 
mutations of three specific elements inactivate the p21 promoter, which suggested that Sp1 
regulates p21 transcription via cis-acting positive and negative regulatory elements in the p21 
promoter (Kavurma and Khachigian, 2004). These two studies suggested that SP1 activates 
or represses the expression of p21. According to these studies, miR-494 can activate or 
repress the expression p21 via the downregulation of Sp1 to regulate the cell cycle. Two 
studies on miR-494 functions in the regulation of cell cycle showed that miR-494 can inhibit or 
accelerate the G1/S transition in the cell cycle. Olaru et al. (2011) suggested that miR-494 
arrests the cell cycle at G1/S transition through downregulation of CDK4, CDK6, CCND1, 
CCNE2 and HDAC1. However, Lim et al (2014) argued that miR-494 indirectly decreased the 
expression of p27 and p21 through directly inhibiting MCC expression, leading to accelerating 
G1/S transition. Therefore, miR-494-mediated downregulation of Sp1 supported these two 
studies that miR-494 can inhibit and accelerate the G1/S transition to regulate cell cycle. Taken 
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together, Sp1 decreases cancer susceptibility and regulates cell cycle through MDM2 and p21 
genes. 
 
Oestrogen responsive transcription factor, Sp1, regulates gene expression through the 
interaction between estrogen receptor alpha (ERα) and Sp1. Several gene expressions, 
including KiSS1 and TNFα, are upregulated or downregulated via the interaction between ERα 
and Sp1 (Li et. al., 2007). The Sp1 and Sp3 directly bind to the GC-rich motif in the promoter 
region of KiSS1. The expression of KiSS1 gene is stably stimulated by the regulation of Sp1 
and Sp3 without the presence of oestrogen (E2). However, ERα is activated with the exposure 
of E2 and binds to the Sp1/Sp3 binding sites to allow the activation or repression of KiSS1 
gene expression, which depends on the binding of a coactivator or corepressor to ERα (Li et. 
al., 2007). Another study on the ERα-Sp1 interaction showed that high E2 level enhances the 
TNFα gene transcription to induce apoptosis. Activated ERα interacts with the two Sp1 binding 
sites in the promoter region of TNFα to increase the expression of TNFα, leading to increased 
caspase-3 expression and induction of apoptosis (Tu et. al., 2013). Therefore, these studies 
suggested that Sp1 can act as both transcriptional activators and repressors in different genes 
through the ERα-Sp1 interaction.  
 
Moreover, several recent studies reported that high E2 levels may cause thrombosis due to 
the downregulation of PS expression. Suzuki et al. (2010) reported that high E2 concentration 
in HepG2 cells results in suppression of PROS1 gene expression through the interaction of 
Sp1 and ERα in the promoter region of PROS1. They suggested that, without E2 stimulation, 
Sp1 and Sp3 upregulate the PROS1 gene expression through other transcriptional 
coactivators. However, with the exposure of E2, ERα interacts with the Sp1 binding sites in the 
promoter region of PROS1. These results in suppression of PROS1 gene expression due to 
histone deacetylation of PROS1 gene. Another study by Tay et al. (2013) further confirmed 
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that increased E2 concentration in HuH-7 cells downregulates PROS1 mRNA expression via 
a direct interaction between miR-494 and the 3’UTR sequence of PROS1 mRNA transcript. In 
this study, the results showed that miR-494 downregulates SP1 mRNA expression through 
the direct interaction of miR-494 and the SP1 mRNA-3’UTR. At least four functional Sp1 
binding sites are identified in the promoter region of PROS1, with two binding sites are 
essential for trans-activating the PROS1 promoter (de Wolf et. al., 2006). These studies 
confirmed that high E2 levels in human liver cells downregulate PS expression through the 
upregulation of miR-494 or the ERα-Sp1 interaction in the PROS1 promoter region. In 
addition, a study by deGraffenired et al. (2002) demonstrated that the expression of Sp1 is 
critical for the ERα gene transcription. They reported that two Sp1 binding sites are identified 
in the three essential elements for full ERα promoter activity. Increased expression of Sp1 and 
Sp3 leads to elevated ERα promoter activity, which suggested that these two transcription 
factors are able to enhance the ERα expression (deGraffenried et. al., 2002). These 
suggested that the downregulation of Sp1 may reduce the repressive effects on the PROS1 
promoter region via ERα-Sp1 interaction (Figure 5.2). Overall, high E2 concentration results in 
decreased PROS1 expression because the Sp1 effects on the ERα promoter region is 
relatively small. 
 
The Sp1 transcription factor targets the PLG promoter region to enhance its promoter activity. 
In this study, computational analyses suggested that a predicted Sp1 binding site is present 
in the promoter region of PLG (section 4.4.2). Furthermore, a study on Sp1 binding sites in 
murine PLG promoter suggested that two Sp1 binding sites are identified in the promoter 
region of murine PLG gene, and are required for the full response of PLG promoter activity. 
The presence of these Sp1 binding sites increased the PLG promoter activity, which suggests 
Sp1 acts as a transcriptional activator in the promoter region of PLG (Gutierrez-Fernandez et. 
al., 2007). This study may explain the downregulation of PLG with the presence of miR-494. 
miR-494 directly represses the mRNA levels of SP1 by binding to the 3’UTR sequence of SP1 
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mRNA transcript, which results in decreased mRNA and protein expression of PLG. However, 
this report studied the promoter region of murine PLG gene in neuroendocrine tissue rather 
than human PLG gene. Therefore, a further study on the interaction between Sp1 and the 
human PLG promoter region is required to confirm miR-494-mediated Sp1 downregulation 
could cause PLG downregulation.  
 
Taken together, we hypothesise oestrogen overexpression results in increased miR-494 
expression. Upregulation of miR-494 downregulates the mRNA expression of Sp1 by directly 
binding to SP1 mRNA-3’UTR sequences, and the Sp1 downregulation results in reduction of 




Figure 5.2 The effects of overexpressed miR-494 by increasing circulating oestrogen levels in 











 SP1  STAT5B 
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The results showed that miR-494 directly downregulates STAT5B mRNA levels by binding to 
the 3’UTR sequence of STAT5B mRNA transcript. STAT5B is an important transcription factor 
in the kinase signalling and various cell signalling pathways, such as the JAK-STAT and the 
Protein kinase B (AKT) signalling pathways (Nyga et. al., 2005; Bibi et. al., 2014; Dalgic et. 
al., 2015). Therefore, miR-494 may indirectly regulate these cell signalling pathways through 
STAT5B repression. Moreover, the STAT5-knockdown mouse model showed increase 
thrombotic susceptibility through accelerating the formation of fibrin, which suggested that 
miR-494 may cause acceleration of fibrin formation through STAT5B downregulation 
(Nordstrom et. al., 2010). 
 
STAT5B may have an important role in coagulation and haemostasis. The absence of 
STAT5B induces fibrin clot formation and increases thrombosis susceptibility. Nordstrom et. 
al. (2010) demonstrated that the mice deficient in STAT5A and STAT5B have a higher risk in 
developing thrombotic diseases. The clotting time is shorter with the absence of STAT5A and 
STAT5B. Moreover, the rate of fibrin polymerisation is significantly increased in the plasma of 
STAT5-deficient mice. However, no changes are found in the thrombin generation (Nordstrom 
et. al., 2010). They suggested that the fibrin clot formation in the STAT5-deficient mice is due 
to the reduction of an unknown circulating inhibitor concentration, rather than the activation of 
intrinsic or extrinsic pathway or increased numbers of thrombin in the plasma (Nordstrom et. 
al., 2010). They also demonstrated that this circulating inhibitor cleaves fibrinopeptide B (FpB) 
through the regulation of thrombin. Another studies on specific deletion of STAT5A and 
STAT5B in hepatocyte causes increased thrombosis susceptibility through significantly 
shortened clotting times (Nordstrom et. al., 2010). Therefore, miR-494 may induce fibrin clot 
formation and increase the thrombosis susceptibility through downregulating STAT5B (Figure 
5.2). Moreover, we believed that one or more hidden STAT5B binding site(s) may reside in 
the PLG promoter to cause the acceleration of fibrin formation through the fibrinolytic pathway, 
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however, further investigations are required for explaining the mechanism of accelerating fibrin 
formation with the absence of STAT5B. 
 
Future directions 
The results of the project provided insight into the potential role(s) of miR-494 in haemostasis 
and thrombosis. The exact roles of miR-494 in coagulation and haemostasis, however, 
warrants further investigation.  
 
The results showed that TF protein expression does not correlated with its mRNA levels 
(chapter 4.2). The discrepancy is possibly caused by measuring the intracellular fraction of a 
naturally secreted protein. The methodology used in this study focused on the intracellular 
protein levels but not the extracellular protein levels. TF is an important coagulation factor in 
the coagulation cascade and haemostasis, therefore, answering the question over the 
negative correlation between TF mRNA and protein expression is necessary. Therefore, the 
TF protein expression at the cell surface, as well as secreted forms, requires further 
investigation. 
 
Apart from regulating PROS1, PLG and C4BPA gene expression, miR-494 may regulate other 
coagulation factors expression. Several studies suggested that Sp1 targets the promoter 
region of multiple coagulation factors to enhance their gene expression. Functional Sp1 
binding sites are identified in the promoter region of several coagulation factors, including 
tissue factor pathway inhibitor 2 (TFPI2), Protein C inhibitor (PCI) and plasminogen activator 
inhibitor-1 (PAI-1). Zerrouqi et al. (2014) reported that functional Sp1 binding sites are found 
in the promoter region of human TFPI2 gene. The expression of TFPI2 is upregulated with the 
presence of Sp1.  In addition, Hayashi et al. (1998) suggested that another Sp1 binding site 
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is identified in the promoter region of human PCI gene, which is an inhibitor of the 
anticoagulant, Protein C. These studies showed that multiple functional Sp1 binding sites were 
identified in the promoter region of several anticoagulant genes, which suggested that miR-
494 may indirectly downregulate these coagulation factors by targeting Sp1. However, Sp1 
binding sites are found in one of the procoagulants, PAI-1, promoter region. The function of 
PAI-1 is to inhibit fibrinolysis via inhibiting t-PA and u-PA. Two adjacent Sp1 binding sites are 
identified in the promoter region of human PAI-1, and Sp1 acts as a transcriptional activator 
in the promoter region of PAI-1 (Chen et. al., 1998). These studies suggested that the effects 
of miR-494 may not be restricted in PS, PLG and C4BPA, and further studies on miR-494 
effects in these coagulation factors are required. 
 
In this study, computational analysis was used for predicting miR-494 binding sites in the 
3’UTR sequence of JUN, SP1 and STAT5B, however, these prediction tools are limited to 
analysing canonical sequences. Novel miR-494 binding sites may still exist in the 3’UTR 
sequences of SP1 and STAT5B mRNA transcripts. Therefore, RNA sequencing may be a 
better methodology to determine the direct interaction between miR-494 and the 3’UTR 
sequence of multiple transcription factors. Moreover, this study focused on determining the 
miR-494 effects on different coagulation factors in HuH-7 cells. The biological activities in 
human cell lines sometimes are different to normal cells. Future studies may also focus on the 
endogenous miR-494 effects in other biologically relevant cell types.  
 
Evidence suggested that miR-223 regulates the coagulation cascade and platelet 
aggregation. miR-223 directly downregulates TF expression to regulate the coagulation 
cascade (Li et. al., 2014b). In platelet aggregation, miR-223 has been shown to target different 
genes that involved in platelets and regulate platelet aggregation, including P2Y12 (Landry et. 
al., 2009). P2Y12 is a seven transmembrane Gi-coupled receptor involved in haemostasis, for 
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example, platelet aggregation and platelet granule secretion. The formation of Ago2-miR-223 
complex negatively regulates mRNA and protein expression of P2Y12 via direct targeting its 
3’UTR sequence. Landry et al. (2009) also suggested that, due to the lack of nuclear 
components, Drosha and DGCR8, in platelets, the pre-miRNAs in platelets are produced and 
processed in megakaryocyte precursor cells and transferred into platelets. Therefore, the roles 
of miRNAs is not only restricted in regulating of the coagulation cascade. The results in this 
study showed that miR-494 regulates multiple coagulation factors expression to promote 
thrombosis, however, it may also have a role in regulating platelet aggregation. Future study 
on the miR-494 effects in platelet aggregation will be investigated in human plasma samples 
and megakaryocytic cell lines. 
 
To conclude, the role of miRNAs in coagulation and haemostasis is still poorly characterised. 
A recent study suggested that miR-494 directly downregulates PROS1 mRNA expression by 
binding to the 3’UTR sequence of its mRNA transcript, which suggested that it may have a 
role in coagulation. This study demonstrated that miR-494 regulates multiple coagulation 
factors and transcription factors expression. miR-494 significantly downregulates the 
expression of PS and PLG, and upregulates the C4BPA expression. Moreover, miR-494 
directly downregulates the Sp1 and STAT5B expression through binding to the SP1 and 
STAT5B mRNA-3’UTR sequences. These suggested that miR-494 may indirectly 
downregulate PLG through repressing Sp1 expression. Taken together, these results 
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1. DMEM medium 
500mL Bottle of DMEM medium 
50mL  fetal calf serum 
5mL Penicillin/streptomycin 
5mL Non-essential amino acid 
solution 
5mL Sodium pyruvate 
The medium was stored at 4°C. 
 
2. RMPI-1640 medium 
500mL Bottle of RMPI-1640 medium 
50mL  fetal calf serum 
5mL Penicillin/streptomycin 
5mL Sodium pyruvate 
The medium was stored at 4°C. 
 
3. Phosphate buffered saline (PBS) 
10 Phosphate buffer saline tablets                                                                 
2L Deionised water 
Ten phosphate buffered saline (PBS) 
tablets from Sigma-Aldrich Co., USA were 
dissolved in 2L deionised water. After it 
fully dissolved, 2L of PBS were aliquotted 
into 6 bottles. The pH were checked by 
using pH meter. All the 6 bottles were 
autoclaved. 
 
4. 2x denaturing solution 
375µL 2-mercaptoethanol 
1 2x denaturing solution 
Add 375µL 2-mercaptoethanol into the 2x 
denaturing solution and mix well. The 
solution was stored at 4°C and warm it 
before use. 
 
5. miRNA wash solution 1 
21mL 100% ethanol 
1 miRNA washing solution 1 
Add 21mL 100% ethanol into the miRNA 
washing solution 1 and mix well. The 




6. miRNA wash solution 2/3 
40mL 100% ethanol 
1 miRNA washing solution 2/3 
Add 40mL 100% ethanol into miRNA 
washing solution 2/3 and mix well. The 
solution was stored at room temperature. 
 
7. 20% sucrose 
4g Sucrose 
20mL  ddH2O 
Sucrose was dissolved in ddH2O to a final 
volume of 20mL. The solution was stored 
at room temperature 
 
8. 4M sodium chloride (NaCl) 
11.69g NaCl 
100mL ddH2O 
NaCl was dissolved in ddH2O to a final 
volume of 100mL. The solution was 








SDS was dissolved in ddH2O to a final 
volume of 100 mL. (Face mask was 
required while handling SDS powder.) 
 
10. 1M Tris-HCl  
121.1g Tris-Base 
1L ddH2O 
Tris-Base was dissolved in approximately 
800 ddH2O. The pH of the solution (pH 6.8 
or 7.4) is required to adjust with 10M HCl, 
the add ddH2O to a final volume of 1L. The 












Tris, glycine and SDS were dissolved in 1L 
ddH2O. (Face mask was required while 
handling SDS powder.) The solution was 
stored at room temperature. 
 




200mL Methanol  
Tris-Base and glycine was dissolved in 
800mL of ddH2O. 200mL of methanol was 
added and stored at 4°C. Transfer buffer 
was made fresh every time. 
 
13. Tris buffered saline with Tween 
20 (TBST) 
37.5mL 4M NaCl8 
50mL 1M Tris-HCl10 
 ddH2O 
0.5mL Tween 20 
37.5mL of NaCl and 50mL Tris-HCL were 
mixed and added ddH2O to a final volume 
of 1L. Tween 20 was added and mix well. 
The solution was stored at room 
temperature. 
 
14. Blotto blocking solution (3%) 
1.2g Skim milk powder 
40mL TBST14 
Skim milk powder was dissolved in TBST14 






15. Western 10x loading dye 
12.5mL Glycerol 
2.5mL 1M Tris-HCl pH6.810 
2.5mL 20% SDS17 
2.5mL Β-Mercaptoethanol 
0.25g  Bromophenol blue 
25mL  ddH2O 
Glycerol, Tris-HCl10, 20% SDS17, 
bromophenol blue and ddH2O were mixed 
together in a 50mL tube. Β-
mercaptoethanol was then added to the 
mixture in a fume hood. The dye was 
stored as 1mL aliquots at -20°C. 
 
16. Whole cell lysis buffer 
2mL ddH2O 
2mL 10% SDS9 
5mL 20% Sucrose7 
0.5mL 1M Tris-HCl10 
0.5mL Β-Mercaptoethanol 
All the solution were combined. The tube 
was wrapped with foil to protect it from 
light. 
 




SDS was dissolved in ddH2O to a final 
volume of 100 mL. (Face mask was 
required while handling SDS powder.) 
 
18. Blotto blocking solution (5%) 
2g Skim milk powder 
40mL TBST14 
Skim milk powder was dissolved in TBST14 



























Appendix IIa. Map of pmiR-Report luciferase plasmid. The site of 3’UTRs insertion is 
highlighted as red.  
The PROS1, JUN, SP1 and 
STAT5B 3’UTRs were inserted 


















        1 GATCAGGCAC CCGGGGCCAG AGACATATGG GCCATACCCC TTAACCCCGG GATGCAAGGT 
       61 AGCATGGGTC CAAGAGACAT GGAAGAGAGA GCCATGAAGC ATTAAAATGC ATGGTGTTGA 
      121 GAAGAATCAG GAGAGGGATA CAAGAGAGGA GATGGGGTCC CGGCACCCAT CTGTATCATC 
      181 AGTGCCTCTT TGAAGGTGGG AAACATTAGT GAAAATTCTG TTGGTGCCAC GCTTTGATGA 
      241 GCATTTGTTT GACCCCAGTT TCTTCTTACA CTTCTTACCC CAGCCTACCC TTCCTGCATT 
      301 TCTCTTCTCA GCTCTTCCAT GATGGATTCC CCCCCCTTTC CTAAAGCCAT CATGCCTTGA 
      361 TAAATATATA TGATCATTGA AATACTTTTT AACAAAAAAC AGATTCTATA TTATTATATA 
      421 TATATATATA TATATAAAGA TATATAGAGA TGCATTCACA GGGGTTGGCT GGGAGGAGGA 
      481 AGACCATTCT GTGACCAAAA TACCTTGGTC ATTTTTTTTA TATTGCCTTA TTTCCCTATG 
      541 GCTGAGCCTT GTTGTGACAC ATCAAGCTTT TCTGTAGATG TTGTCTTGGC TTCCCACCAG 
      601 CTTAAGCGTT CATATGCTCT GCTTTTAGTT CATATATACA TACATAATGT TTTTCCTTTC 
      661 TTAATTTTGT CTTTTTGTTT GGGATCAGCT TCTTGCACTC CTTCCCTAAC TCAACTGTTG 
      721 CCGTCTCATC TTCTCTCATC TGATCACTTC ATGTTTTGTT TTTGTTACTG CCTGGATGAG 
      781 GCACTTCTGT CAATTTTTTC AGGACCTTAG TTCCAGCAGC AGAATGGAAA AATCCTTGAA 
      841 GCCCAGGCTG ATGCTTGAAG TAACTGTGGA GGGAGTGTTC AAAATACTAC TGACGCAGGC 
      901 ACCTTCTTGG CGCTGGAGAG TCAAAGGCAT CTCCCTTCAT TAGCTGCTCT GAGCATCAAG 
      961 AATTAGAAGT CTTTCAGTGG AATTGTACAA GAGTCCCTTT GAAGATAATA ATCTTGGCTC 
     1021 AGTTTGTATA AACTGTCAAA TTTTCAAATA ATAGGTAGGG GGCTTTCACT AGGAAAATCA 
     1081 TGTGCTCAGA AGAGGAAATG ACTCGTAGTC AGGTTCAGGA GTTAGTGGAG TATTTGGACT 
     1141 TTGGTACTGC TGTCTTCCAA GGTAGCTCTA AGTTTTGATG TGTGGGCTTC TGAGTTTATA 
     1201 TTCTGAAAGG AAATACACTT CTTTTGAACA TCCCCACTAG GTTCTTTTCC ATTGTCAATA 
     1261 AGGAGCATCA GCCAGTGAAT CTGTTTCAGG TTTCCATTCT GCAGAACTCC TCCAAAGCAT 
     1321 GTGCTAGTGG CAAGACAGTG GTTCTTATGA TGTTTTCCCT TAACTTTTCC TTGTATGTTC 
     1381 TTGGGTGGTT CCTAAGGGAA AGGGAAGCAC ATGATCATGG GAATGATAGC CCAGAACAAA 
     1441 AAGAAATCTT GTCTTACCAC AGTGTTTTAT AGGAGAGATT GGGAGAAATC ATCCTGTTTT 
     1501 CTCTGTGACC TGATTTCAGA AGAGACTGAT CCAAAAATTA TAACGGCAGG GAACCTAGTG 
     1561 CATTTGGCAC TGAGATTTAA ATGCAACCAG AATTGTCCTC AAGGCCCAGC CATAAAAGCA 
     1621 TTGTCTCTCT CGACCTTCTG GTATCTTGTT AGAGAGCTTT TCACTGTGAG GAAGTGTGGA 
     1681 AAAATAGCTC TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTAAT CTGTTAGGTT 
     1741 GGGGATAGGT TTTCTGCTAG CCAATATTAA AAGAGACCTG CAATAAAAAA ATTACCCTGA 
     1801 TCTGATAGAA AGCAAGTGTT TTTGTATGTG TGGGTGAATG TGTGTTCATG CCCGTATATG 
     1861 TCTACACACA GATGACAAAT TATATTTGAA ATCGTTGGAA AATAAATTCA GATCAAAATG 
     1921 CCTTTCAGGC CCATTACCTA GAAATCTATC TTAAAACCTG GGTATGTTCC TAAGGTCATT 
     1981 TCTTTGCTTA TGCTAAATTA ATTACAATTA TGAATGGAGG ATATTCTACT GTACTTTTTT 
     2041 AAAAAGAAAC TATTTTTGTG TTTGAAAGTG AAACCAACAT CCAGATCTAT AGCAGAGTCC 
     2101 TTATTCTTCT CATAAATCTT TTTACTTTGG CTACAAATAG ATGATGGTAT GATTCTATTA 
     2161 TATATTTTAT ATAAAATCCA TCCAAATTAA GTTTTGGGTA AGTGTGTTGT TTAATCTGAA 
     2221 CTATAGTAAC TTAATACTCT AAACAATAGT TCACTCCATT TGGTCCTTTC TCCACAGATG 
     2281 TAATTATGTT TTCAACTCAG GAACTATGGC AAGGAACTTT CCCCAGATCA AATTCTATTA 
     2341 ACGCTGAGAT ACAAGTCATC CATGCACAGC CACTATCATA CCCTTTATTC TCACTGAAAG 
     2401 GCAGAACTCA GAACCTGTTA TTTTATGTCT GTAATCATGT ACTTTGGCAT CTTTTGGAGG 
     2461 AAAGGGGCAG GATAACTCAC TGGAATGTAC AGTATTTTGC TAGTGCATTT CAAGGAATGG 
     2521 AATCTTCTCC AGTATGAAAT TACCAGATAT AAAATAATGT AATGATGCTG AGGATATAAG 
     2581 CTTTTAGAAG GTAATTTGAT GGTATTTCTT TCTCGAATGA AAAGCTGCTG GTTTACCCTC 
     2641 AACCCTATTC ATTAGCATTA CCATGAGTGA ATTTATATCT AATTATTTCC ACTTGCCCTG 
     2701 TTCTCTTCAC ACCAAGGAAG CTCCAGATCC AGTATCTTGT TTGGCCTCAA AACAGAAGCA 
     2761 GCTTCTTTTG TCTCCCAGCA GTAGTGAGCC ACTCAGTCTC TTCCACAGGA AGTTTGGAGC 
     2821 CTACATTCCT TGAGTCAGGA GCTTATTACA GAAAAACCCC GTTTCCCTGA ACTTTTGGCT 
     2881 AACAGAAATT AATTTAACTG ACATGCATAT TGATTCTGAA ATTTTTTTCC TAAGTTTTTT 
     2941 TCATTTTTTT GAATGAGTTT TTTAAATTTT TTAGATGACC AAAACTTGCA GGGCAGGGGA 
     3001 TGCCCAGAAG AGTGGTGAGA TAGTAAAACA CTTATTCCCT CATCCTTTCA GGTTTTCAGG 
     3061 TTGCCCATTT ATATTCATTT ACATGTCATT TGACTGTCTC ACTTTTTACC CAGAACAGTA 
     3121 ACAACCCACA CCGTCTTCCT TCAGGGATTT CCAACTGGCA CTCTGTGGGT GCTACACAGA 
     3181 ATGCAATTTA ATGGATATTT CTCAGCCTGG TTCAGAATAA ATTGATCCTT TGATCCCAGA 
     3241 AAGTATATAC TGAAGTGTGG GATAAAGATT ATGATTAGGG GAGGGTTGGA GACAAAAGCT 
     3301 GTAAATTACT ATGGCTGATT TATTTCTACT ATATACATAT ATATTTTTTG CTTTTGTATA 
     3361 TCCTATATAG GAAACTAAGC ATTGTATTTT TTTTAACAAA TCTAAAAAAG CACTATGAAC 
     3421 TACAGGTGTT TGACTTTCAA AATATATTTT GTATTGTTAA TATCTTCACA TTGTGTGAAT 
     3481 ACTGGAAGCT GCAGATCTTT GCTAGGACGC AATAAATTTA TATACTTTTT GAGGGGTTCT 
     3541 TCTGGGGTGC TAATCAGGCC CCTGTTATGC TTAGGGGGAG CCCTGGTGCT ACTTGCTTGA 
     3601 AGTTTTCAGT GTAAGTACCC TGATGCCTTT TGGACCTTGG GATCAGATCA AGAGTTTTGG 
     3661 AGATCAGGTA CCAAGGAAAT AAGGACAGTC TAGCTGCCTC AAGTGAGGGG CCCTTTGCAT 
     3721 AGCTCTCCTT CCCCCTCACT GAAGCTGGGT AGCCTATTGG GGTTGAGAGG GAAAATGTGA 
     3781 AATCTCAGAA TTTATCTCCC TTAGAAGAGA GCCAGTAACT TATGTACAAG GATGAAAGAA 
     3841 AGGTCGCAGC AGTAGCTTTG GGGAAAGGGA GGAAGATATG GCACTTCTCC AACCCCGGAA 
     3901 AACATTGCTT TTGAAAACTG CTGATAAAAT ATGAGCCGGT TATTACTTCT GTTTGGGAGA 
     3961 CTGTGCTCTC TGTGGTGCCT CTCTTGGCTC TACTCCACAG ATACCAGACC TCTTCTAAGA 
     4021 GGATGAGCAG ACCAGCTTTG AGGTTGACCT GTTTCTCTTT GTCTGCCTTC CCAAAACACC 
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     4081 AGCCCCCAGG AAGACATTAA GCAGCCTTAA GCTTAAATTC CTACTCCCTC TTCCAAATTT 
     4141 GGCTCACTTG CCTTAGATCC AAGGCAGGGA AAGGAAAAGA AGGGGGGTCT CTGGCTTTAT 
     4201 TACTCCCCTA AGTCTTTACT CTGACTTCCC CAAACCCAGA AAGATTTTCT CCACAGTGTT 
     4261 CATTTGAAAG AGGAGTATTT TGTCCCATTT TCCCCTTCCT CATTATCAAA CAGCCCCAGT 
     4321 CTTCCTTGTC TCTGCTAAGA AAGTAGAGGC ATGATGATCT GCCTCTCAAC TGCCCTAAGT 
     4381 CCTAGCTAAG TATCAGGGGA AAAAAAAAAA AAAAAAGCCT AACAAATGGG ATTAGACTAG 
     4441 GGCTGCAAGT AGTGAGGATT TTGTTGATAC CTCTGCTGGG ATGTGTGCTT TCCCATATCT 
     4501 TGCCTTCAGG AATTACACTG TGCCTTTTCC CCAGGGATAT GGGCTCTGTC TACCCAGTGC 
     4561 TCCAGTTTCC CGGTAACTGC TCTTGAACAT TGTGGACAAG GGCAGGTCTT CATATTTTTG 
     4621 ATCATCCCTT TCTCCCAGTG AAATCCCATA GCCCTTACCT AGAGTCTAGG GCACAAAGAC 
     4681 TTCGGGGAAG ATACACTGAG ATTGACCTGA GGAGACATCT ACACACACCA GTGGCAGCTG 
     4741 CCCCAGGGCC TGCTTCCCCT TCCTAAGTCT GTCATCCTCT GGAAGGGATG GGTGGTGCTC 
     4801 CAATCTCTGG TGCCTAAAAA CCCAAGTTTA TTTCTCTCTT AACACTGGCA ATAACCAGTC 
     4861 CACACCACTG TTGCCTTTTA AAACCTCTTA ATAATCTCAT GCTGTGTTTG TTTTGATTCC 
     4921 AATCCAATTA TCACCAGGGC TGTGTGGGTA AATGCTTTTA AATGCTCTCT CATCTTGTTC 
     4981 TTCCCCCTCA CCCCCCACTC TTAGGTATGT ATGATGCTAA TCTTGTCCCT AAGTAAGTTT 
     5041 CTTCCTGCTC CTTTTGTATC TTCCTTTCTT GTCTTTCCTC CTACCTTTTG TCTCTTGGTG 
     5101 TTTTGGGACT TTTTTTTTTT TTTTTTTGGC CTTTTGTACA AAGATTAGTT TCAATGTAGT 
     5161 CTGTAGCCTC CTTTGTAAAC CAATTAAAAA GTTTTTTAAT AAAAAA 
 









Appendix IId. The 3’UTR sequence of STAT5B inserted into pmiR-Report Luciferase 
plasmid. 
 
